3URGXFW$%3
&OLQLFDO6WXG\3URWRFRO'DWH0DUFK 3DJHRI 
&RQILGHQWLDO 7,7/(3$*(
$5$1'20,=(''28%/(%/,1'678'<72&203$5(
3+$50$&2.,1(7,&6$1'3+$50$&2'<1$0,&6()),&$&<$1'
6$)(7<2)$%3:,7+ 5,78;,0$%,168%-(&76:,7+02'(5$7(
726(9(5(5+(80$72,'$57+5,7,6
7HVW'UXJ  $%3
3URWRFRO1XPEHU  (XGUD&7QXPEHU  
6WXG\3KDVH  
'DWHDQG9HUVLRQ 0DUFK9HUVLRQ
6SRQVRU 
$PJHQ,QF
2QH$PJHQ&HQWHU'ULYH
7KRXVDQG2DNV&$86&OLQLFDO5HVHDUFK2UJDQL]DWLRQ&52 
35$
3DUN/DNH$YHQXH6XLWH
5DOHLJK1&86
0HGLFDO0RQLWRU0HGLFDO([SHUW1RUWK$PHULFD
0'
35$
3KRQH
)$;
(XURSH
0'
3KRQH
)D[6DIHW\&RQWDFW1RUWK$PHULFD3KRQH )D[
(PDLO &+26DIHW\#35$,QWOFRP
(XURSH)$;3KRQH(PDLO &+26DIHW\#35$,QWOFRP
7KLVVWXG\ZLOOEHFRQGXFWHGLQFRPSOLDQFHZLWKWKHSURWRFRO* RRG&OLQLFDO3UDFWLFH
*&3DVVHWIRUWKLQWKH,QWHUQDWLRQDO&RXQFLOIRU +DUPRQLVDWLRQ,&+JXLGHOLQHVRQ
*&3,&+(DQGDSSOLFDEOHORFDOUHJXODWRU\UHTXLUHPHQWV
&21),'(17,$/
7KLVGRFXPHQWLVDFRQILGH QWLDOFRPPXQLFDWLRQRI $PJHQ,QF$FFHSWDQFHRIWKLVGRFXPHQWFRQVWLWXWHV
DJUHHPHQWE\WKHUHFLSLHQWWKDWQRXQSXEOLVKHGLQIRUPDWLRQFRQW DLQHGKHUHLQVKDOOEHSXEOLVKHGRU
GLVFORVHGZLWKRXWSULRUZULWWHQDSSURYDOH[FHSWWKDWWKLVGRFXPHQWPD\EHGLVFORVHGWR WKHDSSURSULDWH
,QVWLWXWLRQDO5HYLHZ%RDUGV,QGH SHQGHQW(WKLFV&RPPLWWHHVXQGHUWKHFRQGLWLRQWK DWWKH\NHHSLW
FRQILGHQWLDOPPDPPD
PPD
PPD
1&71XPEHU
7KLV1&7QXPEHUKDVEHHQDSSOLHGWRWKHGRFXPHQW
IRUSXUSRVHVRISRVWLQJRQFOLQLFDOWULDOVJRY
PPD
PPD
PPD
PPD
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 3 of 77  
Confidential   Investigator 
I have read and agree to the protocol 20130108, entitled â€œA Randomized, Double-Blind 
Study to Compare Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of ABP 
798 with Rituximab in Subjects with Moderate to  Severe Rheumatoid Arthritis.â€ I am aware 
of my responsibilities as an Investigator under the guidelines of GCP, local regulations (as 
applicable) and the study protocol.  I agree to conduct the study according to these responsibilities and to appropriately direct and assist the staff under my control, who will 
be involved in the study. 
 
Clinical Site:   
  
Site Number:  
 
Site Principal Investigator:  
   
Print Name  Title 
    
Signature  Date 
  
Coordinating Investigator Signature:  
   
Print Name  Title 
 
Institution/ Country 
   
Signature  Date 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 4 of 77  
Confidential2 SYNOPSIS 
NAME OF SPONSOR:  Amgen  PROTOCOL No.: 20130108  
NAME OF STUDY TREATMENT:  ABP 798
TITLE OF STUDY:  A Randomized, Double-Blind Study to Compare Pharmacokinetics and 
Pharmacodynamics, Efficacy and Safety of ABP 798 wi th Rituximab in Subjects with Moderate to 
Severe Rheumatoid Arthritis  
STUDY CENTERS:   Approximatel y 80 sites in Europe and North America 
STUDY PERIOD:   Approximately 300 subjects will be randomized in a 
1:1:1 ratio to receive ABP 798 or rituximab (US) or rituximab (EU).  
The end of trial will be the date when the last subject has completed 
their last stud y assessment.  PHASE OF DEVELOPMENT:  
Phase 1/3 
PLANNED STUDY DATES: 29 April 2016 to 28 February 2018.  The expected enrollment 
duration is 12 months, and each sub ject will participate for up to 52 weeks.  
OBJECTIVES:   
Primary Objective:  The primary objective for this study is to demonstrate pharmacokinetic (PK) 
similarity (as assessed principally by area under the serum concentration- time curve [AUC] from 
time 0 extrapolated to infinity [AUC inf] and the maximum observed serum concentration [C max] 
following the 2nd infusion of 1st dose) of ABP 798 following 2 intravenous (IV) infusions of 
1000 mg each, relative to that of 2 IV infusions of 1000 mg each of rituximab (US) and of rituximab (EU). 
Secondary Objective(s):  The secondary objectives are 
ï‚·to demonstrate PK similarity between rituximab (US) and rituximab (EU) as
assessed by AUC
inf and by C max after second infusion of the first dose
ï‚·to assess the clinical efficacy  of ABP 798 compared with rituximab
ï‚·to assess the safety and immunogenicity of ABP 798 compared with rituximab.
STUDY DESIGN AND METHODOLOGY:  This is a randomized, double-blind, active-controlled 
3-arm study in adult subjects with moderate to severe rheumatoid arthritis (RA) who have had an 
inadequate response or intolerance to other di sease-modifying anti-rheumatic drugs (DMARDs), 
which must include intolerance or inadequate response to one or more tumor necrosis factor 
(TNF) inhibitor therapies.  Approximately 300 subjects (100 per treatment group) will be enrolled.  
The subjects will be randomized to receive either ABP 798 1000 mg x 2 (treatment group A) 
infusions given 2 weeks apart, or rituximab (US) (t reatment group B), or rituximab (EU) (treatment 
group C) 1000 mg x 2, given 2 weeks apart in a double-blinded fashion.  Randomization will be 
stratified by geographic region, seropositivity (r heumatoid factor [RF]-positive and/or cyclic 
citrullinated peptide [CCP]-positive vs. RF-negat ive, and CCP-negative), and number of prior 
biologic therapies used for RA (1 vs. > 1).   An independent data monitoring committee (DMC) wi ll evaluate the safety data throughout the 
study, including an initial safety analysis after t he first 18 subjects have received the first dose 
(1000 mg x 2 infusions of either ABP 798 or rituximab [EU] or rituximab [US]). 
At week 24, the subjects in treatment groups A and C will continue with and receive the second 
dose of the same treatment, and the subjects in treatment group B will transition to treatment 
group A1 and receive ABP 798 1000 mg x 2 as their second dose.  Retreatment may occur 
earlier, ie, anytime from week 16 to week 24, in individual subjects, if necessary in the opinion of 
the Investigator. The end of study (EOS) will be at week 48 (or 24 weeks after the first infusion of the second dose 
for subjects retreated before week 24), and a fi nal analysis will be performed when all subjects 
have completed or have had the opportunit
y to complete the week 48/EOS assessments.
STUDY POPULATION AND MAIN CRITERIA FOR INCLUSION/EXCLUSION:  
Subjects cannot be randomized before all inclusion criteria (including test results) are confirmed. 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 5 of 77  
Confidential   Inclusion Criteria:   
1. Subjects must sign an Institutional  Review Board (IRB)/Independent Ethics 
Committee (IEC)-approved informed consent form before any study specific 
procedures are preformed 
2. Men or women â‰¥  18 and â‰¤ 80 years old 
3. Subjects must be diagnosed with RA as determined by meeting 2010 American 
College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for RA 
4. Duration of RA of at least 6 months 5. Active RA defined as â‰¥ 6 swollen joints and â‰¥ 6 tender joints (based on 66/68 joint 
count excluding distal interphalangeal joints) at screening and baseline and at least one of the following at screening:  
ï‚· erythrocyte sedimentation rate (ESR) â‰¥ 28 mm/hr 
ï‚· serum C-reactive protein (CRP) > 1.0 mg/dL 
6. Subjects have had an inadequate response or  intolerance to other DMARDs (which 
must include intolerance or inadequate response to one or more TNF inhibitor therapies) 
7. Subjects must be taking methotrexate (MTX) for â‰¥ 12 consecutive weeks and be on a 
stable dose of MTX 7.5 to 25 mg/week for â‰¥ 8 weeks prior to receiving the 
investigational product (IP), and be willing to remain on a stable dose throughout the 
study 
8. Subjects on non-steroidal anti-inf lammatory drugs (NSAIDs) or low potency 
analgesics such as tramadol, soma compounds, fioricet, fiorinal, should be on stable doses for â‰¥ 2 weeks prior to screening 
9. Subjects on oral corticosteroids, ( â‰¤ 10 mg prednisone or equivalent), should be on 
stable doses for â‰¥ 4 weeks prior to screening 
10. Subject has no known history of active tuberculosis 
11. Subject has a negative test for tuberculo sis during screening defined as either: 
ï‚· negative purified protein derivative (PPD) < 5 mm of induration at 48 to 
72 hours after test is placed) 
OR 
ï‚· negative Quantiferon test 
12. Subjects with a positive PPD and a history of Bacillus Calmette-GuÃ©rin vaccination 
are allowed with a negative Quantiferon test 
13. Subjects with a positive PPD test (wit hout a history of Bacillus Calmette-GuÃ©rin 
vaccination) or subjects with a positive or  indeterminate Quantiferon test are allowed 
if they have all of the following:   
ï‚· no symptoms per tuberculosis worksh eet provided by the Sponsor, Amgen 
ï‚· documented history of treatment with a TB prophylaxis regimen, with at least 
4 weeks of prophylaxis therapy complet ed at the time of screening.  If a 
subject has completed at least 4 weeks of prophylaxis therapy, and their 
regimen requires >4 weeks therapy, the subject must be deemed able and willing to complete the entire prophylaxis regimen in accordance with local 
guidance 
ï‚· no known exposure to a case of acti ve tuberculosis after most recent 
prophylaxis  
ï‚· no evidence of active tuberculosis on chest radiograph within 3 months prior 
to the first dose of IP 
 
Exclusion Criteria: Rheumatoid arthritis related 
1. Class IV RA (Hochberg et al, 1992) according to ACR revised response criteria  
2. Feltyâ€™s syndrome (RA, splenomegaly, and granulocytopenia) 
3. History of prosthetic or native joint infection 
Other medical conditions 
4. Planned surgical intervention dur ing the duration of the study 
5. 
Active infection or histor y of infections as follows:
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 6 of 77  
Confidential   ï‚· any active infection for which systemic anti-infectives were used within 4 
weeks prior to first dose of IP  
ï‚· a serious infection, defined as requiring hospitalization or IV anti-infectives 
within 8 weeks prior to the first dose of IP  
ï‚· recurrent or chronic infections or other active infection that, in the opinion of 
the Investigator, might cause this study to be detrimental to the subject 
6. Known history of human immunodeficiency virus 7. Hepatitis B surface antigen (HbsAg) or Hepa titis B core antibody (anti-HBc) positivity 
at screening (unless documentation of hepatit is B virus immunization) or Hepatitis C 
virus (HCV) antibody positivity at screening 
8. Uncontrolled, clinically significant systemic disease such as diabetes mellitus, 
cardiovascular disease including severe hear t failure (New York Heart Association 
[NYHA] class IV), or severe uncontrolled cardiac disease, renal disease, or liver 
disease  
9. Malignancy within 5 years EXCEPT treated and considered cured cutaneous 
squamous or basal cell carcinoma, in situ cervical cancer, OR in situ breast ductal 
carcinoma 
10. History of neurologic symptoms suggesti ve of central nervous system demyelinating 
disease 
11. Major chronic inflammatory disease or connective tissue disease other than RA, with 
the exception of secondary SjÃ¶grenâ€™s syndrome 
12. Concurrent medical condition that, in the opinion of the Investigator, could cause this 
study to be detrimental to the subject 
Laboratory abnormalities 
13. Laboratory abnormalities at screening,  including any of the following: 
ï‚· hemoglobin < 9 g/dL 
ï‚· platelet count < 100,000/mm
3 
ï‚· white blood cell count < 3,000 cells/mm3 
ï‚· aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) 
â‰¥ 2.0 x the upper limit of normal 
ï‚· creatinine clearance < 50 mL/min (Cockroft-Gault formula) 
ï‚· any other laboratory abnormality, which, in the opinion of the Investigator, will 
prevent the subject from completing the study or will interfere with the interpretation of the study results 
Washouts and non-permitted drugs 
14. Any of the following within 28 days prior to first dose of IP: 
ï‚· intra-articular (IA) hyaluronic acid injections 
ï‚· IA, intramuscular (IM), or IV cortic osteroids, including adrenocorticotropic 
hormone 
15. Non-biologic DMARDs, including Janus kinase inhibitors such as tofacitinib, other 
than MTX within 28 days prior to first dose of IP, except as below: 
ï‚· leflunomide (unless an active washout with cholestyramine has been 
performed), cyclosporine, azathioprine, tacrolimus excluded within 3 months 
prior to first dose of IP  
ï‚· use of IM or oral gold excluded within 6 months prior to first dose of IP  
ï‚· cytotoxic agents such as cyclophos phamide, D-penicillamine excluded within 
6 months prior to first dose of IP  
ï‚· received IV gamma-globulin or Prosorba column therapy excluded within 
3 months prior to first dose of IP 
16. Use of commercially available or investigat ional biologic therapies for RA as follows: 
ï‚· anakinra, etanercept within 1 month prior to first dose of IP 
ï‚· infliximab, abatacept, tocilizumab, golimumab, certolizumab , adalimumab 
within 3 months prior to first dose of IP 
ï‚· other experimental or commercially avai lable biologic therapies for RA within 
3 months or 5 half-lives (whichever is  longer) prior to first dose of IP 
17. Live vaccines within 28 da
ys prior to the first dose of IP
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 7 of 77  
Confidential   18. Chronic use of high poten cy narcotic analgesics such as morphine or morphine 
derived medications, fentanyl, codeine, hy dromorphone, levorphanol, meperidine, 
methadone, oxycodone or hydrocodone at screening 
19. Previous receipt of rituximab, a biosimilar of rituximab, or ocrelizumab  
20. Currently is enrolled in or has not ye t completed at least 30 days or 5 half-lives 
(whichever is longer) since ending other inve stigational device or investigational drug, 
including vaccines, or subject is rece iving other investigational agent(s) 
General 
21. For women:  pregnant or breast feeding, or planning to become pregnant while 
enrolled in the study and for 12 mont hs after the last dose of IP 
22. Sexually active subjects and their pa rtners who are of childbearing potential (ie, 
neither surgically sterile nor postmenopausal) and not agreeing to use adequate contraception (eg, true abstinence, sterili zation, birth control pills, Depo-Provera 
injections, or contraceptive implants) whil e on study and for 12 months after the last 
dose of investigational product.   
23. Known sensitivity to mammalian cell deriv ed drug products or hype rsensitivity to the 
active substance or to any of t he excipients of ABP 798 or rituximab 
24. Any physical or psychiatric disorder whic h, in the opinion of the Investigator, will 
prevent the subject from completing the study or interfere with the interpretation of 
the study results  
25. Any disorder that compro mises the ability of the subject to give written informed 
consent and/or to comply with study procedures 
26. Active substance abuse, in the opinion of the Investigator (within 24 weeks of 
screenin
g) 
NUMBER OF SUBJECTS:  Approximately 300 subjects will be randomized in a 1:1:1 ratio to 
receive ABP 798, rituximab (US), or rituximab (EU) , stratified by geographic region, seropositivity 
(RF-positive and/or CCP-positive vs. RF-negat ive and CCP-negative) and number of prior 
biologic therapies used for RA (1 vs. > 1).  The sample size will provide > 90% power to 
demonstrate similarity on the primary PK endpoints,  based on an assumption of between-subject 
variability (as measured by coefficient of variation) of 40%, true geometric mean ratio (GMR) of 1 
among ABP 798, rituximab (US), or rituximab (EU), a margin of (0.8, 1.25), and 15% dropout by 
week 24.  The PK similarity will be tested between ABP 798 versus rituximab (US) and ABP 798 
versus rituximab (EU), each with a significance level of 0.05.  The similarity between rituximab 
(US) and rituximab (EU) will be evaluated as well.
STUDY TREATMENT(S):   
Test Product, Dose and Mode of Administration: 
ABP 798 (Treatment A) 500 mg/mL given at 1000 mg IV x 2 infusions 2 weeks apart 
Reference Therapy, Dose and Mode of Administration: 
Rituximab (US) (Treatment B) or rituximab (EU)  (Treatment C) 500 mg/mL given at 1000 mg IV x 
2 infusions 2 weeks apart 
DURATION OF TREATMENT:   Subjects will receive a first dose (2 infusions at days 1 and 15), 
followed by a second dose (2 infusions 2 weeks apart beginning at week 24 or earlier, ie, anytime from week 16 to week 24, in individual subjects, if necessary in the opinion  of the Investigator), 
with assessment until week 48 (or 24 weeks after the first infusion of the second dose for subjects retreated before week 24), plus a screening period of up to 4 weeks, for a total of up to 52 weeks.  A total of 2 doses will be administered during t he study; each dose will co nsist of 2 infusions, 
2 weeks apart. 
STUDY EVALUATIONS:   
Primary Criteria:  
ï‚· AUC inf, Cmax following the second infusion of the first dose 
Secondary Criteria: ï‚· Percent of subjects with complete depleti on in CD19+ cell count from day 1 to day 3 
ï‚· Disease Activity Score (DAS)28-CR P change from baseline at week 24 
ï‚· ACR20,  ACR50 and ACR70   
ï‚· AUC from time 0 on day 1 prior to the first infusion of the first dose to 14 days postdose 
(day 15) (AUC
0-14 day ), AUC from time 0 to week 12 (AUC 0-12 wk ), C max following the first 
infusion of the first dose 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 8 of 77  
Confidential   Safety Criteria: 
ï‚· Treatment-emergent adverse events (AEs) and serious adverse events (SAEs) 
ï‚· Clinically significant changes in laboratory values and vital signs  
ï‚· Incidence of antidrug antibodies  
STATISTICAL METHODS:  
The PK similarity will be demonstrated by compar ing the 90% confidence interval (CI) for the 
GMR of test (ABP 798)-to-reference (ri tuximab [US] or rituximab [EU]) and rituximab [US] to  
rituximab [EU] for AUC inf and for Cmax following the second infusion of the first dose with the 
bounds of 0.8 to 1.25 , where Î±=0.05.  PK parameters w ill be calculated using non-
compartmental methods.  Point estimates and CIs for the GMR will be estimated from an 
analysis of covariance model using the PK Analys is Set, consisting of all randomized subjects 
with an evaluable serum concentration-time profile.  
   
Clinical equivalence will be evaluated for DAS28- CRP at week 24 using the Full Analysis Set 
consisting of all randomized subjects.  If PK similarity is establis hed between rituximab (US) 
and rituximab (EU), the 2 arms will be comb ined into a single reference arm for the 
primary assessment of clinical equivalence between ABP 798 and rituximab.  The results 
for ABP 798 vs. rituximab (EU) and ABP 798 vs . rituximab (US) will be provided for 
descriptive purposes. If PK similarity is  not established, the ABP 798 arm will be 
compared to each of the individual rituximab arms separately to establish clinical equivalence of ABP 798 to the individual reference arms.   
 
With the planned sample size, there is 94% probability that the 90% CI of the difference 
between the ABP 798 arm and the pooled rituximab (rituximab[EU] and rituximab[US]) 
arm and 83% probability that the 90% CI of t he difference between test (ABP 798) and 
reference (US-licensed rituximab or EU-autho rized rituximab) in DAS28-CRP change from 
baseline at week 24 will fall into the equivalence margin of Â± 0.6 (EULAR response criteria), 
assuming a standard deviation of 1.4 ( Volkmann et al, 2010 ). DAS28-CRP at other timepoints 
and ACR20, 50 and 70 will be summarized descriptively.  
 In addition, all categorical variables will be summarized using the number and percent of 
subjects falling into each category and all cont inuous variables will be summarized using mean, 
standard error or standard deviation, median, minimum, maximum, and number of subjects.  
Safety endpoints will be summarized descriptively as well, based on all randomized subjects 
who received at least one infusion of IP 
(ie, Safet y Anal ysis Set ). 
DATE AND VERSION: 20 March 2018; Version 4.0
 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 9 of 77  
Confidential3 TABLE OF CONTENTS 
1Â  TITLE PAGE .................................................................................................. 1 Â 
2Â  SYNOPSIS ..................................................................................................... 4 Â 
3Â  TABLE OF CONTENTS ................................................................................. 9 Â 
4Â  LIST OF ABBREVIATIONS AND DEFINITION OF TERMS ....................... 14 Â 
5Â  ETHICS ........................................................................................................ 17 Â 
5.1Â  Ethics Committee ....................................................................................... 17 Â 
5.2Â  Ethical Conduct of the Study .................................................................... 17 Â 
5.3Â  Subject Information and Consent ............................................................. 17 Â 
6Â  INTRODUCTION .......................................................................................... 19 Â 
6.1Â  Disease Review .......................................................................................... 19 Â 
6.2Â  Rituximab .................................................................................................... 19 Â 
6.3Â  Compound Review ..................................................................................... 20 Â 
6.4Â  Study Rationale .......................................................................................... 20 Â 
7Â  STUDY OBJECTIVES ................................................................................. 22 Â 
7.1Â  Primary Study Objective ............................................................................ 22 Â 
7.2Â  Secondary Study Objectives ..................................................................... 22 Â 
8Â  INVESTIGATIONAL PLAN .......................................................................... 23 Â 
8.1Â  Overall Study Design and Plan ................................................................. 23 Â 
8.2Â  Discussion of Study Design ...................................................................... 24 Â 
8.3Â  Study Duration ............................................................................................ 24 Â 
8.4Â  Study Population ........................................................................................ 25 Â 
8.4.1Â  Inclusion Criteria ........................................................................................... 25Â 
8.4.2Â  Exclusion Criteria ......................................................................................... 26 Â 
8.4.3Â  Withdrawal and Replacement of Subjects .................................................... 28 Â 
8.4.3.1Â  Criteria for Subject Withdrawal ..................................................................... 28 Â 
8.4.3.2Â  Evaluations at Withdrawal ............................................................................ 28 Â 
8.4.3.3Â  Replacement of Subjects ............................................................................. 29 Â 
8.5Â  Treatment .................................................................................................... 29 Â 
8.5.1Â  Treatments Administered ............................................................................. 29 Â 
8.5.2Â  Study Treatment Formulation ....................................................................... 30 Â 
8.5.2.1Â  Study Drug ................................................................................................... 30 Â 
8.5.2.2Â  Comparator .................................................................................................. 30 Â 
8.5.3Â  Study Treatment Labeling and Packaging ................................................... 31 Â 
8.5.4Â  Blinding of Study Medication ........................................................................ 31 Â 
8.5.5Â  Study Treatment Storage and Accountability ............................................... 31 Â 
8.5.5.1Â  Study Treatment Storage ............................................................................. 31 Â 
8.5.5.2Â  Study Treatment Accountability .................................................................... 32 Â 
8.5.6Â  Dose Adjustments and Dose Escalation ...................................................... 32 Â 
8.5.7Â  Prior and Concomitant Therapy ................................................................... 32 Â 
8.5.7.1Â  Permitted Concomitant Treatments (Medications and Therapies) ............... 32 Â 
8.5.7.2Â  Prohibited Concomitant Medications ............................................................ 33 Â 
8.5.7.3Â  Rescue Medication ....................................................................................... 33 Â 
8.5.7.4Â  Prophylactic Treatment ................................................................................ 34 Â 
8.5.7.5Â  Other Concomitant Medications and Treatments ......................................... 34 Â 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 10 of 77  
Confidential   8.5.8Â  Treatment Compliance ................................................................................. 34 Â 
8.5.9Â  Assignment to Treatment ............................................................................. 34 Â 
8.5.10Â  Unblinding Procedures ................................................................................. 35 Â 
8.6Â  Efficacy, Pharmacokinetic/Pharmacodynamic, and Safety Variables ... 35 Â 
8.6.1Â  Efficacy, Pharmacokinetic/Pharmacodynamic, and Safety Measurements 
Assessed ...................................................................................................... 35 Â 
8.6.1.1Â  Pharmacokinetic/Pharmacodynamic Endpoints ........................................... 35Â 
8.6.1.2Â  Efficacy Measurements ................................................................................ 39 Â 
8.6.1.2.1Â  Efficacy Criteria ............................................................................................ 39 Â 
8.6.1.3Â  Safety Measurements .................................................................................. 39 Â 
9Â  STUDY EVALUATIONS BY VISIT .............................................................. 40 Â 
9.1Â  Screening .................................................................................................... 40 Â 
9.1.1Â  Screen Failures ............................................................................................ 40 Â 
9.2Â  Baseline (Day 1, first day of treatment, Week 0) ..................................... 41 Â 
9.3Â  Day 2 ............................................................................................................ 42 Â 
9.4Â  Day 3 ............................................................................................................ 42 Â 
9.5Â  Day 15 (Week 2) .......................................................................................... 42 Â 
9.6Â  Day 16 .......................................................................................................... 43 Â 
9.7Â  Day 17 .......................................................................................................... 43 Â 
9.8Â  Week 4 (ï‚±  2 days) ....................................................................................... 43 Â 
9.9Â  Week 8 (ï‚±  2 days) ....................................................................................... 43 Â 
9.10Â  Week 12 (ï‚±  2 days) ..................................................................................... 44 Â 
9.11Â  Week 24 ....................................................................................................... 44 Â 
9.12Â  Week 26 ....................................................................................................... 45 Â 
9.13Â  Week 30 (ï‚±  2 days) ..................................................................................... 45 Â 
9.14Â  Week 40 (ï‚±  3 days) ..................................................................................... 46 Â 
9.15Â  Week 48 (EOS) ............................................................................................ 46 Â 
10Â  METHODS OF ASSESSMENT .................................................................... 47 Â 
10.1Â  Rheumatoid Arthritis Assessments ......................................................... 47 Â 
10.2Â  Pregnancy Test ........................................................................................... 47 Â 
10.3Â  Physical Examination ................................................................................ 48 Â 
10.4Â  Vital Signs ................................................................................................... 48 Â 
10.5Â  Electrocardiogram ...................................................................................... 48 Â 
10.6Â  Tuberculosis Testing ................................................................................. 48 Â 
10.7Â  Chest Radiography .................................................................................... 49 Â 
10.8Â  Clinical Laboratory Testing ....................................................................... 49 Â 
10.9Â  Blood Samples for Pharmacokinetic Analysis ........................................ 50 Â 
10.10Â  Blood Samples for Pharmacodynamic Analysis ..................................... 50 Â 
11Â  SAFETY DATA COLLECTION, RECORDING, AND REPORTING ............ 51 Â 
11.1Â  Adverse Events .......................................................................................... 51 Â 
11.1.1Â  Definition of Adverse Events ........................................................................ 51 Â 
11.1.2Â  Reporting Procedures for Adverse Events ................................................... 51 Â 
11.2Â  Serious Adverse Events ............................................................................ 52 Â 
11.2.1Â  Definition of Serious Adverse Events ........................................................... 52 Â 
11.2.2Â  Reporting Procedures for Serious Adverse Events ...................................... 52 Â 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 11 of 77  
Confidential11.3Â  Adverse Events of Special Interest .......................................................... 54 Â 
11.4Â  Pregnancy Reporting ................................................................................. 54 Â 
12Â  DATA MANAGEMENT AND STATISTICAL ANALYSIS ............................ 56 Â 
12.1Â  Data Management ....................................................................................... 56 Â 
12.2Â  Sample Size Estimation ............................................................................. 56 Â 
12.3Â  Statistical Analysis Plan ............................................................................ 56 Â 
12.4Â  Randomization ............................................................................................ 56 Â 
12.5Â  Analysis Populations ................................................................................. 57 Â 
12.5.1Â  Full Analysis Set ........................................................................................... 57 Â 
12.5.2Â  Per-protocol Set ........................................................................................... 57 Â 
12.5.3Â  Safety Analysis Set ...................................................................................... 57 Â 
12.5.4Â  Pharmacokinetic Analysis Set ...................................................................... 57 Â 
12.5.5Â  Per-protocol Pharmacokinetic Analysis Set ................................................. 57 Â 
12.6Â  Statistical Methods ..................................................................................... 58 Â 
12.6.1Â  Missing Data ................................................................................................. 58Â 
12.6.2Â  Demographic and Baseline Data .................................................................. 58 Â 
12.6.3Â  Subject Disposition ....................................................................................... 58 Â 
12.6.4Â  Pharmacokinetics ......................................................................................... 59 Â 
12.6.5Â  Pharmacodynamics ...................................................................................... 59 Â 
12.6.6Â  Efficacy ......................................................................................................... 59 Â 
12.6.7Â  Safety ........................................................................................................... 60 Â 
12.6.7.1Â  Investigational Product Administration ......................................................... 61 Â 
12.6.7.2Â  Adverse Events ............................................................................................ 61 Â 
12.6.7.3Â  Immunogenicity ............................................................................................ 61 Â 
12.6.7.4Â  Concomitant Medications and Therapies ..................................................... 61 Â 
12.6.7.5Â  Clinical Lab oratory Test ................................................................................ 61 Â 
12.6.7.6Â  Vital Signs and Physical Examinations ........................................................ 62 Â 
12.6.8Â  Interim Analysis ............................................................................................ 62 Â 
12.6.9Â  Data Monitoring Committee .......................................................................... 62 Â 
13Â  MONITORING PROCEDURES (QUALITY ASSURANCE) ......................... 63 Â 
13.1Â  Routine Monitoring .................................................................................... 63 Â 
13.2Â  Inspections and Auditing Procedures ...................................................... 63 Â 
14Â  STUDY MANAGEMENT AND MATERIALS ............................................... 65 Â 
14.1Â  Electronic Case Report Forms .................................................................. 65 Â 
14.2Â  Data Collection ........................................................................................... 65 Â 
14.3Â  Source Documents Maintenance .............................................................. 66 Â 
14.4Â  Record Maintenance .................................................................................. 66 Â 
14.5Â  Confidentiality ............................................................................................ 67 Â 
15Â  ADMINISTRATION PROCEDURES ............................................................ 68 Â 
15.1Â  Regulatory Approval .................................................................................. 68 Â 
15.2Â  Protocol Amendments ............................................................................... 68 Â 
15.3Â  Protocol Adherence and Deviations ......................................................... 69 Â 
15.4Â  Publication Policy ...................................................................................... 69 Â 
15.5Â  Clinical Study Report ................................................................................. 70Â 
15.6
Â  Contractual and Financial Details ............................................................. 70 Â 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 12 of 77  
Confidential15.7Â  Compensation ............................................................................................ 70 Â 
15.8Â  Discontinuation of the Study .................................................................... 70 Â 
15.9Â  Study Center File Management ................................................................. 70 Â 
16Â  REFERENCE LIST ...................................................................................... 72 Â 
17Â  APPENDICES .............................................................................................. 74 Â 
17.1Â  Appendix 1: Elements of Informed Consent ............................................ 74 Â 
17.2Â  Appendix 2: American College of Rheumatology Revised Criteria for 
the Classification of Functional Capacity in RA ...................................... 75 Â 
17.3Â  Appendix 3: DAS28 and ACR Core Set Measurements .......................... 76 Â 
17.4Â  Appendix 4: Subjective Assessment Scales ........................................... 77 Â 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 13 of 77  
ConfidentialLIST OF TABLES 
Table 1.  Schedule of Assessments and Procedures ................................................ 36 Â 
LIST OF FIGURES 
Figure 1.  Study Diagram .............................................................................................. 24 Â 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 14 of 77  
Confidential4 LIST OF ABBREVIATIONS AND DEFINITION OF TERMS 
Term  Definition  
ACR American College of Rheumatology 
ACR20 20% improvement in ACR core set measurements 
ACR50 50% improvement in ACR core set measurements 
ACR70 70% improvement in ACR core set measurements 
AE Adverse event  
ALT Alanine aminotransferase  
anti-HBc Hepatitis B core antibody 
AST Aspartate aminotransferase  
AUC Area under the serum concentration-time curve 
AUC 0-14 day  AUC from time 0 on day 1 prior to the first infusion of the 
first dose to 14 days postdose (day 15) 
AUC 0-12wk AUC from time 0 on day 1 prior to the first infusion of the 
first dose to week 12  
AUC inf AUC from time 0 on day 1 prior to the first infusion of the first dose extrapolated to infinity 
CCP Cyclic citrullinated peptide 
CDC Complement-mediated cytotoxicity
CFR Code of Federal Regulations 
CI Confidence interval
C
max Maximum observed serum concentration 
COX-2 Cyclooxygenase-2
CRO Clinical research organization 
CRP C-reactive protein
CTCAE Common Terminology Criteria for Adverse Events  
DAS Disease Activity Score  
DMARD Disease-modifying antirheumatic drug 
DMC Data Monitoring Committee 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 15 of 77  
Confidential   ECG Electrocardiogram 
eCRF Electronic case report form 
EDC Electronic data capture 
EOI End of infusion 
EOS End of study 
ESR Erythrocyte sedimentation rate 
EULAR European League Against Rheumatism  
FAS Full analysis set 
FDA Food and Drug Administration 
GCP Good Clinical Practice 
GEE Generalized estimating equation 
GMR Geometric mean ratio 
HAQ-DI Health Assessment Questionnaire â€“ Disability Index 
HBsAg Hepatitis B surface antigen 
HCV Hepatitis C virus 
HCG Human chorionic gonadotrophin 
IA Intra-articular 
ICF Informed consent form 
ICH International Council for Harmonisation 
IEC Independent Ethics Committee 
Ig Immunoglobulin 
IL Interleukin 
IM Intramuscular  
IP Investigational Product 
IRB Institutional Review Board 
IV Intravenous 
IXRS Interactive voice and web response system 
Î»z Terminal elimination rate constant 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 16 of 77  
Confidential   MedDRA Medical Dictionary for Regulatory Activities 
MTX Methotrexate 
NSAID Non-steroidal anti-inflammatory drug 
NYHA New York Heart Association  
PD Pharmacodynamic(s) 
PIN Personal Identification Number 
PK Pharmacokinetic(s) 
PPD Purified protein derivative  
RA Rheumatoid arthritis 
RD Risk difference 
RF Rheumatoid factor 
rituximab (EU) European Medicines  Agency EU-authorized rituximab 
rituximab (US) Food and Drug Administration US-licensed rituximab 
RR Risk ratio 
SAA Serum amyloid protein  
SAE Serious adverse event 
SAP Statistical Analysis Plan 
SC Subcutaneous(ly) 
Scn Screening 
SUSAR Suspected unexpected serious adverse reactions 
t1/2 Terminal elimination half-life 
tmax Time of C max 
TNF Tumor necrosis factor 
VAS Visual analogue scale 
WHO World Health Organization 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 17 of 77  
Confidential5 ETHICS 
5.1 Ethics Committee 
This study will be conducted in compliance with Institutional Review Board 
(IRB)/Independent Ethics Committee (IEC) and International Council for Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines - including Title 21 Part 56 of the US 
Code of Federal Regulations (CFR) relating to IRBs/IECs and GCP as described in the 
US Food and Drug Administration (FDA) CFR (21 CFR Â§ 50, 56, 312) - in accordance with applicable ICH regulations regarding clinical safety data management (E2A, E2B[R3]), European Community directives 2001/20, 2001/83, 2003/94 and 2005/28 as 
enacted into local law, and with ICH guidelines regarding scientific integrity (E4, E8, E9, 
and E10).  In addition, this study will adhere to all local regulatory requirements, and requirements for data protection. 
Before initiating a trial/study, the Investigator/institution must have written and dated 
approval/favorable opinion from the IRB/IEC for the study protocol/amendment(s), 
written informed consent form (ICF), any consent form updates, subject recruitment 
procedures (eg, advertisements), and any writt en information to be provided to subjects 
and a statement from the IRB/IEC that they comply with GCP requirements.  The IRB/IEC approval must identify the protocol version as well as the documents reviewed. 
5.2 Ethical Conduct of the Study 
This study will be conducted in accordance with the Note for Guidance on GCP (ICH Harmonised Tripartite Guideline E6 (R1); FDA CFR (21 CFR Â§ 50, 56, 312)), the general principles indicated in the Declaration of Helsinki and all applicable regulatory requirements. 
5.3 Subject Information and Consent 
The Investigator will explain the benefits and risks of participation in the study to each 
subject or the subjectâ€™s legally acceptabl e representative and obtain written informed 
consent.  Written informed consent must be obtained prior to the subject entering the 
study and before initiation of any study related procedure (including administration of investigational product).  
The Sponsor will provide a sample ICF, based on the elements of informed consent in 
Section 17.1 .  The final, version dated, form must be agreed to by the Sponsor and the 
IRB/IEC and will contain all elements in the sample form, in language readily understood by the subject.  Each subjectâ€™s original consent form, personally signed and dated by the 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 18 of 77  
Confidential   subject or by the subjectâ€™s legally acc eptable representative, and by the person who 
conducted the informed consent discussion, will be retained by the Investigator.  The 
Investigator will supply all enrolled subjects with a copy of their signed ICF. 
The ICF may need to be revised during the study should important new information 
become available that may be relevant to the safety of the subject.  In this instance, approval should always be given by the IRB/IE C, and existing subjects informed of the 
changes and re-consented.  This is documented in the same way as previously 
described. 
The Investigator should, with the consent of the subject, inform the subjectâ€™s primary 
physician about the subjectâ€™s participation in the clinical study as needed. 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 19 of 77  
Confidential6 INTRODUCTION 
6.1 Disease Review 
Rheumatoid arthritis (RA) is a chronic infl ammatory disease of unknown etiology in 
which patients exhibit systemic features such as fatigue, low grade fever, weight loss, 
anemia, and increased systemic levels of acute phase reactants (eg, erythrocyte 
sedimentation rates [ESR] and C-reactive protein [CRP]; Aletaha et al, 2010).  Although 
the disease is systemic in nature, the primary target tissues are the synovial membrane, 
cartilage, and bone (McInnes et al, 2007), which exhibit uncontrolled synovium/pannus proliferation and excess fluid production, and ultimately undergo progressive destructive 
arthropathy (Aletaha et al, 2010 ; Choy et al, 2001).   
The pathologic processes in RA appear to be primarily driven by B cells, by autoantibody 
production, by antigen presentation to T cells, and by promoting inflammation through the activation of macrophages and dendritic cells (Tuscano and Sands, 2009 ).  
Targeting of B cells has become a major therapeutic approach in RA.  Therapeutic 
monoclonal antibodies have been developed with the aim of depleting B cells and 
reducing the RA disease process.  The depleting activity of B cell-targeted monoclonal antibodies largely relies on 2 Fc-dependent mechanisms: antibody-dependent cell-mediated cytotoxicity and complement-medi ated cytotoxicity (CDC).  The engagement of 
effector cells by therapeutic monoclonal ant ibodies involves the interaction of the 
monoclonal antibodies Fc with Fc Î³ receptors on the surface of natural killer cells, 
monocytes/macrophages, or neutrophils ( BlÃ¼ml et al, 2013 ).  
6.2 Rituximab 
Rituximab (RituxanÂ®, MabTheraÂ®) is a genetically engineered chimeric murine/human 
monoclonal immunoglobulin (Ig) G1 kappa antibody directed against the B cell specific 
CD20 antigen.  In RA patients, treatment with rituximab induces depletion of peripheral 
B lymphocytes, with the majority of patients demonstrating near complete depletion (CD19 counts below the lower limit of quantification, 20 cells/ Î¼L) within 2 weeks after 
receiving the first dose.  Most patients showed peripheral B cell depletion for at least 
6 months.  A small proportion of patients (~4%) had prolonged peripheral B cell 
depletion lasting more than 3 years after a single course of treatment (Biogen Idec, 2013).  
Total serum Ig levels, IgM, IgG, and IgA were reduced at 6 months with the greatest 
change observed in IgM.  In RA patients during repeated rituximab treatment, 23.3%, 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 20 of 77  
Confidential5.5%, and 0.5% of patients experienced decreases in IgM, IgG, and IgA concentrations 
below the lower limit of normal, respectively, at any time after receiving rituximab.  The clinical consequences of decreases in Ig levels in RA patients are unclear ( Biogen Idec, 
2013). 
Treatment with rituximab in patients with RA is associated with reduction of certain 
biologic markers of inflammation such as interleukin (IL)-6, CRP, serum amyloid protein (SAA), S100 A8/S100 A9 heterodimer complex (S100 A8/9), anti-cyclic citrullinated 
peptide (anti-CCP), and rheumatoid factor (RF; Biogen Idec, 2013 ). 
Rituximab is indicated, in combination with methotrexate (MTX), for the treatment of 
adult patients with moderately- to severely-active RA who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.  Rituximab is approved for use in other indications such as non-Hodgkin lymphoma, chronic 
lymphocytic leukemia, granulomatosis with polyangiitis, and microscopic polyangiitis 
(Biogen Idec, 2013).   
6.3 Compound Review 
ABP 798 is being developed as a biosimilar candidate to RituxanÂ®, MabTheraÂ® 
(rituximab) for the treatment of RA and other indications.  The active ingredient of ABP 798 is an anti-CD20 monoclonal antibody which has the same ami no acid 
sequence as rituximab.  ABP 798 has the same pharmaceutical form and dosage 
strength as FDA US-licensed rituximab [rituximab (US), Rituxan
Â®] and European 
Medicines Agency EU-authorized rituximab [rituximab (EU), MabTheraÂ®]. 
Similarity of ABP 798 to rituximab has been shown using bioanalytical methods and pre-
clinical studies.  As outlined in the guide line on similar biological medicinal products 
containing monoclonal antibodies, applicants are expected to provide data on similarity 
of pharmacokinetics (PK)/pharmacody namics (PD), safety and efficacy.    
Refer to the Investigatorâ€™s Brochure for additional information.   
6.4 Study Rationale 
In the US, EU, and much of the world, laws, regulations, and guidances have been or are being put in place to increase availability of biological treatments by developing and licensing biosimilar products (CHMP/437/04 Rev 1; EMEA/CHMP/BWP/247713/2012; EMEA/CHMP/BMWP/42832/2005 Rev.1 ; US FDA 2012a; US FDA 2012b).  A biosimilar 
product, generally, is one that is highly similar to a licensed biologic reference product, 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 21 of 77  
Confidential   and there are no clinically meaningful differences between the biosimilar and reference 
products in terms of safety, purity, and pot ency.  Biosimilarity is demonstrated by the 
totality of the evidence, including quality, nonclinical, and clinical evidence.  The 
analytical and nonclinical similarity of ABP 798 and rituximab are summarized in the 
Investigatorâ€™s Brochure.  The current study is designed to demonstrate the PK similarity and that there is no clinically meaningful difference between ABP 798 and rituximab in terms of safety, efficacy, and immunogenicity. 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 22 of 77  
Confidential7 STUDY OBJECTIVES  
7.1 Primary Study Objective 
The primary objective for this study is to demonstrate PK similarity (as assessed 
principally by area under the serum concent ration-time curve [AUC] from time 0 
extrapolated to infinity [AUC inf] and the maximum observed  serum concentration [C max], 
following the 2nd infusion of 1st dose) of ABP 798 following 2 intravenous (IV) infusions of 
1000 mg each, relative to that of 2 IV infusions of 1000 mg each of rituximab (US) and of rituximab (EU). 
7.2 Secondary Study Objectives 
The secondary objectives are  
ï‚·to demonstrate PK similarity between rituximab (US) and rituximab (EU) as
assessed by AUC inf and by C max after second infusion of the first dose
ï‚·to assess the clinical efficacy of ABP 798 compared with rituximab
ï‚·to assess the safety and immunogenicity of ABP 798 compared with rituximab.
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 23 of 77  
Confidential   8 INVESTIGATIONAL PLAN 
8.1 Overall Study Design and Plan 
This is a randomized, double-blind, active-controlled 3-arm study in adult subjects with 
moderate to severe RA who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (DMARD s) (which must include intolerance or 
inadequate response to one or more TNF inhibitor therapies).  Approximately 300 subjects (100 per treatment group) will be enrolled.  The subjects will be randomized to receive either 2 IV infusions of ABP 798, 1000 mg each, given 2 weeks apart (treatment group A), or 2 IV infusions of rituximab (US) 1000 mg each, given 2 weeks 
apart (treatment group B) or 2 IV infusions of rituximab (EU), 1000 mg each, given 2 
weeks apart (treatment group C), in a double-blinded fashion.  A total of 2 doses will be administered during the study; each dose consists of 2 infusions, 2 weeks apart. 
An independent data monitoring committee (DMC) will evaluate the safety data 
throughout the study, including an initial safety analysis after the first 18 subjects have 
been dosed (1000 mg x 2 infusions of either ABP 798 or rituximab [EU] or rituximab 
[US]).   
At week 24, the subjects in treatment groups A and C will continue with and receive the 
second dose of the same treatment, and the subjects in treatment group B will transition 
to become treatment group A1 and receive the second dose with ABP 798.  Retreatment 
may occur earlier, ie, anytime from week 16 to week 24 in individual subjects if necessary in the opinion of the Investigator. 
The end of study (EOS) will be at week 48  (or 24 weeks after the first infusion of the 
second dose for subjects retreated before week 24), and a final analysis will be 
performed when all subjects have completed or have had the opportunity to complete 
the week 48/EOS assessments.  Figure 1 is a summary of the study design. 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 24 of 77  
Confidential   Figure 1.  Study Diagram  
     
   R    
   A  Treatment Group A  
 S  N  ABP 798 1000 mg x 2 (N=100)  
 C  D    Treatment Group A1*  
 R  O    ABP 798 1000 mg x 2 (N=200)  
 E  M       
 E  I  Treatment Group B  
 N  Z  Rituximab (US) 1000 mg x 2 (N=100)  
 I  A   
 N  T       
 G  I       
   O  Treatment Group C  Treatment Group C*  
   N  Rituximab (EU) 1000 mg x 2 (N=100) Rituximab (EU) 1000 mg x 2 (N=100)
      
    
     
        End of Study week 48  
 Up to 28 
days                                                   Week 16-24 Final Analysis week 48  
* Retreatment will begin at week 24 or earlier, ie, anytime from week 16 to week 24 in individual subjects if 
necessary in the opinion of the Investigator. 
8.2 Discussion of Study Design 
This study is randomized and double-blind to prevent bias in treatment allocation and in 
the subjective assessment of effect.   
8.3 Study Duration 
Subjects will receive investigational product (IP) first dose (2 infusions at days 1 and 15), followed by a second dose (2 infusions 2 weeks apart beginning at week 24 or earlier, ie, 
anytime from week 16 to week 24 in individual subjects if necessary in the opinion of the 
Investigator) with assessment until week 48 (or 24 weeks after the first infusion of the second dose for subjects retreated before week 24), plus a screening period of up to 4 weeks, for a total of up to 52 weeks.  A total of 2 doses will be administered during the study; each dose consists of 2 infusions, 2 weeks apart. 
Enrollment will continue until approximately 300 subjects have been randomized to 
treatment.  The end of trial will be the date when the last subject has completed  their last 
study assessment. 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 25 of 77  
Confidential   8.4 Study Population 
8.4.1 Inclusion Criteria 
Subjects MUST  satisfy all of the following entry criteria before they will be allowed to 
participate in the study: 
1. Subjects must sign an IRB/IEC-approved informed consent form before any 
study specific procedures are preformed 
2. Men or women â‰¥ 18 and â‰¤  80 years old 
3. Subjects must be diagnosed with RA as determined by meeting 2010 American 
College of Rheumatology (ACR)/European League Against Rheumatism 
(EULAR) classification criteria for RA 
4. Duration of RA of at least 6 months 5. Active RA defined as â‰¥  6 swollen joints and â‰¥  6 tender joints (based on 
66/68 joint count excluding distal interphalangeal joints) at screening and baseline and at least one of the following at screening:  
ï‚· ESR â‰¥ 28 mm/hr 
ï‚· serum CRP > 1.0 mg/dL 
6. Subjects have had an inadequate response or intolerance to other DMARDs 
(which must include intolerance or inadequate response to one or more TNF 
inhibitor therapies) 
7. Subjects must be taking MTX for â‰¥ 12 consecutive weeks and be on a stable 
dose of MTX 7.5 to 25 mg/week for â‰¥ 8 weeks prior to receiving the 
investigational product, and be willing to remain on a stable dose throughout the 
study 
8. Subjects on non-steroidal anti-inflammatory drugs (NSAIDs) or low potency 
analgesics such as tramadol, soma compounds, fioricet, fiorinal, should be on stable doses for â‰¥ 2 weeks prior to screening 
9. Subjects on oral corticosteroids, ( â‰¤ 10 mg prednisone or equivalent), should be 
on stable doses for â‰¥ 4 weeks prior to screening 
10. Subject has no known history of active tuberculosis 
11. Subject has a negative test for tuberculosis during screening defined as either: 
ï‚· negative purified protein derivative (PPD) < 5 mm of induration at 48 to 
72 hours after test is placed) 
 OR 
ï‚· negative Quantiferon test 
12. Subjects with a positive PPD and a history of Bacillus Calmette-GuÃ©rin 
vaccination are allowed with a negative Quantiferon test 
13. Subjects with a positive PPD test (without a history of Bacillus Calmette-GuÃ©rin 
vaccination) or subjects with a positive or indeterminate Quantiferon test are allowed if they have all of the following:   
ï‚· no symptoms per tuberculosis wor ksheet provided by the Sponsor, Amgen 
ï‚· documented history of treatment with a TB prophylaxis regimen, with at least 
4 weeks of prophylaxis therapy completed at the time of screening.  If a 
subject has completed at least 4 weeks of prophylaxis therapy, and their 
regimen requires >4 weeks therapy, the subject must be deemed able and willing to complete the entire prophylaxis regimen in accordance with local guidance 
ï‚· no known exposure to a case of active tuberculosis after most recent 
prophylaxis  
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 26 of 77  
Confidential   ï‚· no evidence of active tuberculosis on chest radiograph within 3 months prior 
to the first dose of investigational product  
 
8.4.2 Exclusion Criteria 
If any of the following apply, the subject MUST  NOT  enter the study: 
Rheumatoid arthritis related 
1. Class IV RA ( Hochberg et al, 1992 ) according to ACR revised response criteria 
(Section 17.2) 
2. Feltyâ€™s syndrome (RA, splenomegaly, and granulocytopenia) 
3. History of prosthetic or native joint infection 
Other medical conditions 
4. Planned surgical intervention during the duration of the study 
5. Active infection or history of infections as follows: 
ï‚· any active infection for which systemic anti-infectives were used within 
4 weeks prior to first dose of investigational product  
ï‚· a serious infection, defined as requiring hospitalization or IV anti-infectives 
within 8 weeks prior to the first dose of investigational product  
ï‚· recurrent or chronic infections or other active infection that, in the opinion of 
the Investigator, might cause this study to be detrimental to the subject 
6. Known history of human immunodeficiency virus 7. Hepatitis B surface antigen (HbsAg)  or Hepatitis B core antibody (anti-HBc)  
positivity at screening (unless documentation of hepatitis B virus immunization) 
or hepatitis C virus (HCV) antibody positivity at screening 
8. Uncontrolled, clinically significant systemic disease such as diabetes mellitus, 
cardiovascular disease including severe heart failure (New York Heart 
Association [NYHA] class IV), or severe uncontrolled cardiac disease, renal disease, or liver disease  
9. Malignancy within 5 years EXCEPT treated and considered cured cutaneous 
squamous or basal cell carcinoma, in situ cervical cancer, OR in situ breast ductal carcinoma 
10. History of neurologic symptoms suggestive of central nervous system 
demyelinating disease 
11. Major chronic inflammatory disease or connective tissue disease other than RA, 
with the exception of secondary SjÃ¶grenâ€™s syndrome 
12. Concurrent medical condition that, in the opinion of the Investigator, could cause 
this study to be detrimental to the subject 
Laboratory abnormalities 
13. Laboratory abnormalities at screening, including any of the following: 
ï‚· hemoglobin < 9 g/dL 
ï‚· platelet count < 100,000/mm
3 
ï‚· white blood cell count < 3,000 cells/mm3 
ï‚· aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) 
â‰¥ 2.0 x the upper limit of normal 
ï‚· creatinine clearance < 50 mL/m in (Cockroft-Gault formula) 
ï‚· any other laboratory abnormality, which, in the opinion of the Investigator, will 
prevent the subject from completing the study or will interfere with the 
interpretation of the study results 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 27 of 77  
Confidential   Washouts and non-permitted drugs 
14. Any of the following within 28 days prior to first dose of investigational product: 
ï‚· intra-articular (IA) hyaluronic acid injections 
ï‚· IA, intramuscular (IM), or IV corticosteroids, including adrenocorticotropic 
hormone 
15. Non-biologic DMARDs, including Janus kinase  inhibitors such as tofacitinib, other 
than MTX within 28 days prior to first dose of investigational product, except as 
below: 
ï‚· leflunomide (unless an active washout with cholestyramine has been 
performed), cyclosporine, azathioprine, tacrolimus excluded within 3 months 
prior to first dose of investigational product  
ï‚· use of IM or oral gold excluded within 6 months prior to first dose of IP  
ï‚· cytotoxic agents such as cyclophosphamide, D-penicillamine excluded within 
6 months prior to first dose of investigational product  
ï‚· received IV gamma-globulin or Prosorba column therapy excluded within 
3 months prior to first dose of investigational product 
16. Use of commercially available or investigational biologic therapies for RA as 
follows: 
ï‚· anakinra, etanercept within 1 month prior to first dose of IP 
ï‚· infliximab, abatacept, tocilizumab, golimumab, certolizumab, adalimumab 
within 3 months prior to first dose of investigational product 
ï‚· other experimental or commercially ava ilable biologic therapies for RA within 
3 months or 5 half-lives (whichever is longer) prior to first dose of 
investigational product 
17. Live vaccines within 28 days prior to the first dose of investigational product 18. Chronic use of high potency narcotic analgesics such as morphine or morphine 
derived medications, fentanyl, codeine, hydromorphone, levorphanol, 
meperidine, methadone, oxycodone, or hydrocodone at screening 
19. Previous receipt of rituximab, a bi osimilar of rituximab, or ocrelizumab  
20. Currently is enrolled in or has not yet completed at least 30 days or 5 half-lives 
(whichever is longer) since ending other investigational device or investigational 
drug, including vaccines, or subject is receiving other investigational agent(s) 
General 
21. For women:  pregnant or breast feeding, or planning to become pregnant while 
enrolled in the study and for 12 months after the last dose of investigational 
product 
22. Sexually active subjects and their partners who are of childbearing potential (ie, 
neither surgically sterile nor postmenopausal) and not agreeing to use adequate 
contraception (eg, true abstinence, sterilization, birth control pills, Depo-Provera injections, or contraceptive implants) while on study and for 12 months after the 
last dose of investigational product.   
23. Known sensitivity to mammalian cell derived drug products or hypersensitivity to 
the active substance or to any of the excipients of ABP 798 or rituximab 
24. Any physical or psychiatric disorder which, in the opinion of the Investigator, will 
prevent the subject from completing the study or interfere with the interpretation 
of the study results  
25. Any disorder that compromises the ability of the subject to give written informed 
consent and/or to comply with study procedures 
26. Active substance abuse, in the opinion of the Investigator (within 24 weeks of 
screening) 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 28 of 77  
Confidential   8.4.3 Withdrawal and Replacement of Subjects 
8.4.3.1 Criteria for Subject Withdrawal 
Subjects have the right to withdraw from the study at any time and for any reason 
without prejudice to future medical care by the physician or at the institution. 
Subjects (or a legally acceptable representative) can decline to continue receiving 
investigational product and/or other protocol required therapies or procedures at any 
time during the study, but continue participating in the study.  If this occurs, the Investigator is to discuss with the subject the appropriate processes for discontinuation from investigational product or other protocol required therapies and must discuss with 
the subject the options for continuation of the Schedule of Assessments and Procedures 
(Table 1 ) and collection of data, including endpoints and AEs.  The Investigator must 
document the change to the Schedule of Assessments ( Table 1) and the level of follow-
up that is agreed to by the subject (eg, in person, by telephone/mail, through family/friends, in correspondence/communication with other physicians, from review of 
the medical records).   
Withdrawal of consent for a study means that the subject does not wish to receive 
further protocol-required therapies or procedures, and the subject does not wish to or is unable to continue further study participation.  Subject data up to withdrawal of consent 
will be included in the analysis of the study, and, where permitted, publicly available data 
can be included after withdrawal of consent.  The Investigator is to discuss with the subject appropriate procedures for withdrawal from the study.   
Reasons for removal from protocol-required investigational products or procedural 
assessments might include: 
ï‚· subject request to end IP administration 
ï‚· safety concern (eg, due to an AE, failure to follow contraception, and/or protocol 
requirements)  
ï‚· pregnancy 
Reasons for removal of a subject from the study might include: 
ï‚· withdrawal of consent from study 
ï‚· lost to follow-up  
ï‚· decision by Sponsor  
8.4.3.2 Evaluations at Withdrawal 
For any subject who is withdrawn before completing all study visits, the Investigator should: 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 29 of 77  
Confidential   ï‚· Perform all the procedures scheduled for week 48/EOS.  The week 48/EOS 
assessments will be performed no later than 14 days after 
withdrawal/discontinuation (unless the subject withdraws consent to do so). 
ï‚· Complete all appropriate electronic case report form (eCRF) screens, providing 
the date of and explanation for the subjectâ€™s withdrawal/discontinuation. 
ï‚· When indicated, arrange for appropriate follow up and/or alternative medical 
care for the discontinued subject.  
If the subject fails to attend a scheduled termination visit, there will be at least 2 attempts 
to contact the subject via telephone and 2 written communications.  If these receive no reply, the subject will be considered lost to follow up. 
8.4.3.3 Replacement of Subjects 
Subjects who are withdrawn will not be replaced.  However, sufficient subjects will be 
included to ensure the minimum sample size defined (see Section 12.2). 
8.5 Treatment 
8.5.1 Treatments Administered 
The Investigator must ensure that the investigational products will be used only in 
accordance with the protocol. 
Subjects will be randomly assigned at Baseline (day 1) to 1 of 3 treatment groups.  The 
first dose will be administered as follows: 
ï‚· Treatment A:  ABP 798 1000 mg IV on study days 1 and 15  
ï‚· Treatment B:  Rituximab (US) 1000 mg IV on study days 1 and 15  
ï‚· Treatment C:  Rituximab (EU) 1000 mg IV on study days 1 and 15  
At week 24, the subjects in treatment groups A and C will continue with and receive the 
second dose with the same treatment (ABP 798 1000 mg x 2 and rituximab (EU) 
1000 mg x 2, respectively), and the subjects in treatment group B will transition to 
treatment group A1 and receive the second dose of ABP 798 1000 mg x 2.  Retreatment may occur earlier, ie, anytime from week 16 to week 24 in individual subjects, if necessary in the opinion of the Investigator.  The EOS will be at week 48 (or 24 weeks 
after the first infusion of the second dose for subjects retreated before week 24).  A total 
of 2 doses will be administered during the study; each dose will consist of 2 infusions. 
No dose reductions or changes will be allowed.   ABP 798/rituximab will be administered after all other procedures are completed for each 
visit.  Investigational product will be administered only as an IV infusion by a healthcare 
professional with appropriate medical support to manage severe infusion reactions.  Do 
3URGXFW$%3
&OLQLFDO6WXG\3URWRFRO'DWH0DUFK 3DJHRI 
&RQILGHQWLDOQRWDGPLQLVWHUDVDQ,9SXVKRUEROXV6XEMHFWVVKRXOGUHFHLYHSUHPHGLFDWLRQVEHIRUH
HDFKLQIXVLRQ
3UHPHGLFDWLRQVVKRXOGEHJLYHQDFFRUGLQJWRORFDOJXLGDQFHDQGWKHDSSURYHGSURGXFW
ODEHO7KHVHVKRXOGJHQHUDOO\LQFOXGHDFHWDPLQRSKHQDQGDQDQW LKLVWDPLQHDQG
PHWK\OSUHGQLVRQHPJ,9RUHTXLYDOHQWPLQXWHVEHIRUHHDFK LQIXVLRQ
,9LQIXVLRQVVKRXOGEHSHUIRUPHGDFFRUGLQJWRORFDOJXLGDQFHDQGWKHDSSURYHGSURGXFW
ODEHO5LWX[DQ3URGXFW,QVHUW0DE7KHUD3URGXFW,QVHUW
,QYHVWLJDWLRQDOSURGXFWLQIXVLRQUHDFWLRQVVKRXOGEHKDQGOHGDF FRUGLQJWRORFDOJXLGDQFH
DQGWKHDSSURYHGSURGXFWODEHO
$OOVXEMHFWVZLOOFRQWLQXHRQDVWDEOHGRVHRI07;Â•PJZH HNRUDORUVXEFXWDQHRXV
>6&@IRUWKHGXUDWLRQRIWKHLUSDUWLFLSDWLRQLQWKHVWXG\DV SUHVFULEHGE\WKHWUHDWLQJ
SK\VLFLDQ:KHQSRVVLEOHWKHGRVHRI07;VKRXOGEHWDNHQRQW KHVDPHGD\RIWKH
ZHHN,QWKHHYHQWWKDWDVXEMHFWGHYHORSV07;UHODWHGVLGHHI IHFWVHJ
PXFRVLWLVVWRPDWLWLVDGRVHUHGXFWLRQRUFKDQJHRIURXWHVKRXOGEHFRQVLGHUHG
 6WXG\7UHDWPHQW)RUPXODWLRQ
 6WXG\'UXJ
$%3LVDJHQHWLFDOO\HQJLQHHUHGFKLPHULFPXULQHKXPDQPRQRFORQDO,J*NDSSD
DQWLERG\GLUHFWHGDJDLQVWWKH&'DQWLJHQ$%3KDVDQDSSUR[LPDWHPROHFXODU
ZHLJKWRIN'$%3LVSURGXFHGE\PDPPDOLDQFHOO&KLQHVH+DPVWHU2YDU\
VXVSHQVLRQFXOWXUHLQDQXWULHQWPHGLXP$%3LVDVWHULOHFOHDUSUHVHUYDWLYHIUHHOLTXLGFRQFHQWUDWHIRU,9DGPLQLVWUDWLRQ$%3LVVXSSOLHGDWDFRQFHQWUDWLRQRIPJP/LQHLWKHUPJP/RUPJP/VLQJOHXVHYLDOV2QO\PJP/YLDOVZLOOEHXVHGLQWKLVVWXG\7KHSURGXFWLV IRUPXODWHGLQSRO\VRUEDWH
 PJP/VRGLXPFLWUDWHGLK\GUDWH PJP/VRGLXPFKORULGH  PJP/DQG
:DWHUIRU,QMHFWLRQ7KHS+LV 
6LWHVZLOOSUHVFULEH07;DFFRUGLQJWRVWDQGDUGORFDOJXLGDQFH
 &RPSDUDWRU
5LWX[LPDELVDJHQHWLFDOO\HQJLQHHUHGFKLPHULFPXULQHKXPDQPRQRFORQDO,J*NDSSD
DQWLERG\GLUHFWHGDJDLQVWWKH&'DQWLJHQKDYLQJDQDSSUR[LPD WHPROHFXODUZHLJKWRI
N'DQGELQGLQJDIILQLW\IRUWKH&'DQWLJHQRIDSSUR[LPDWH O\Q05LWX[LPDELV
SURGXFHGE\PDPPDOLDQFHOO&KLQHVH+DPVWHU2YDU\VXVSHQVLRQFXOWXUHLQDQXWULHQW
PHGLXPFRQWDLQLQJWKHDQWLELRWLFJHQWDPLFLQ%RWKULWX[LPDE8 6DQGULWX[LPDE(8
KDYHWKHVDPHSURGXFWIRUPXODWLRQRIDVWHULOHFOHDUFRORUOHV VSUHVHUYDWLYHIUHHOLTXLGCC
I
CCICCI CCI
3URGXFW$%3
&OLQLFDO6WXG\3URWRFRO'DWH0DUFK 3DJHRI 
&RQILGHQWLDOFRQFHQWUDWHIRU,9DGPLQLVWUDWLRQ5LWX[LPDE86DQGULWX[LPD E(8LVVXSSOLHGDWD
FRQFHQWUDWLRQRIPJP/LQHLWKHUPJP/RUPJP /VLQJOHXVHYLDOV
2QO\PJP/YLDOVZLOOEHXVHGLQWKLVVWXG\7KHSURGXF WLVIRUPXODWHGLQ
SRO\VRUEDWH PJP/VRGLXPFLWUDWHGLK\GUDWH PJP/VRGLX PFKORULGH
 PJP/DQGZDWHUIRULQMHFWLRQ7KHS+LV 
5LWX[LPDE86DQGULWX[LPDE(8ZLOOEHSURYLGHGIURPFRPPHUFLDOVXSSOLHV
 6WXG\7UHDWPHQW/DEHOLQJDQG3DFNDJLQJ
$PDQXDOFRQWDLQLQJGHWDLOHGLQIRUPDWLRQUHJDUGLQJWKHODEHOLQJ SDFNDJLQJVWRUDJH
SUHSDUDWLRQDQGDGPLQLVWUDWLRQRIHDFKLQYHVWLJDWLRQDOSURGXFW HJLQYHVWLJDWLRQDO
SURGXFW>V@DQGFRPSDUDWRUSURGXFW>V@DQGEULHILQIRUPDWLRQDER XWRWKHUSURWRFROUHTXLUHG
WKHUDSLHVZLOOEHSURYLGHGVHSDUDWHO\LQWKH3KDUPDF\*XLGH
 %OLQGLQJRI6WXG\0HGLFDWLRQ
6LQFHWKHLQYHVWLJDWLRQDOSURGXFWFRQWDLQHUVDUHGLIIHUHQWIRU$%3DQGULWX[LPDE
LQYHVWLJDWLRQDOSURGXFW$%3RUULWX[LPDEZLOOEHSUHSDUHGE\DQXQEOLQGHG
3KDUPDFLVWRUGHVLJQHHIRUDGPLQLVWUDWLRQWRWKHVXEMHFW7KH VXEMHFWVWKH6SRQVRU
$PJHQGHVLJQDWHG35$DQGRWKHUFOLQLFDOVLWHVWDIIZLOOEH EOLQGHGWRWKH
LQYHVWLJDWLRQDOSURGXFWDOORFDWLRQIRUHDFKVXEMHFW5DQGRPL]DWLRQGDWDZLOOEHNHSW
VWULFWO\FRQILGHQWLDOILOHGVHFXUHO\E\WKH6SRQVRURUGHVLJQ HHDQGDFFHVVLEOHRQO\WR
DXWKRUL]HGSHUVRQVSHU6SRQVRURUGHVLJQHHÂ¶VVWDQGDUGRSHUDWL QJSURFHGXUHV623V
XQWLOWKHWLPHRIXQEOLQGLQJ6HOHFW35$VWDIIHJFOLQLFDOUH VHDUFKDVVRFLDWHVZKRZLOO
QRWEHLQYROYHGLQWKHPRQLWRULQJRUWKHGDLO\RSHUDWLRQVRIWK HVWXG\ZLOOEHXQEOLQGHGWR
VXEMHFWLQYHVWLJDWLRQDOSURGXFWDOORFDWLRQLQRUGHUWRSHUIRUP LQYHVWLJDWLRQDOSURGXFW
DFFRXQWDELOLW\
)RUGHWDLOVRQWKHHPHUJHQF\SURFHGXUHIRUXQEOLQGLQJRILQGLYL GXDOVXEMHFWVVHH
6HFWLRQ EHORZ
$WUDQGRPL]DWLRQUDQGRPL]DWLRQQXPEHUVZLOOEHDVVLJQHGWRHDF KVXEMHFWE\WKH
LQWHUDFWLYHYRLFHDQGZHEUHVSRQVHV\VWHP,;56
 6WXG\7UHDWPHQW6WRUDJHDQG$FFRXQWDELOLW\
,WLVIRUELGGHQWRXVHLQYHVWLJDWLRQDOGUXJPDWHULDOIRUSXUSRVHVRWKHUWKDQWKRVHGHILQHG
LQWKLVSURWRFRO
 6WXG\7UHDWPHQW6WRUDJH
,QYHVWLJDWLRQDOSURGXFWVKRXOGEHVWRUHGLQDVHFXUHOLPLWHGDFFHVVORFDWLRQ$%3DQGULWX[LPDEVKRXOGEHVWRUHGSURWHFWHGIURPOLJKWDW Âƒ&WR Âƒ& DQGDFFRUGLQJWRWKHCC
I
CCICCICCI
CCICCI
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 32 of 77  
Confidential   storage and expiration information (where required) provided on the label that is affixed 
to the package containing the investigational product.  Do not freeze or shake. 
8.5.5.2 Study Treatm ent Accountability 
All supplies of study medication will be accounted for in accordance with GCP.  There 
will be an investigational product accountability record and the pharmacist, or designee, 
should maintain accurate records of the disposition of all study medication supplies received during the study.  These records should include the amounts and dates that clinical drug supplies were received and destroyed/returned to Amgen or its designee.  If 
errors or damages in the clinical drug supply shipments occur, the Investigator should 
contact Amgen or its designee immediately.  Copies of the study medication accountability records will be provided by each Investigator for inclusion in the Trial Master File after database lock.  The study monitor will periodically check the supplies of study medication held by the Investigator or pharmacist to verify accountability of all 
medication used. 
The Investigator will administer the medication only to the identified subjects of this 
study, according to the procedures described in this study protocol.  After the end of the study, all unused medication and all medication containers should be destroyed or 
returned to Amgen or its designee, as appropriate, for destruction.  In either instance, 
complete documentation will be returned to the Sponsor. 
8.5.6 Dose Adjustment s and Dose Escalation 
There are no recommended dose reductions or escalations for the investigational products (ABP 798 or rituximab).   
All AEs should be reported in accordance with Section 11 of the protocol. 
8.5.7 Prior and Concomitant Therapy 
8.5.7.1 Permitted Concomitant Treat ments (Medications and Therapies) 
The following concomitant medications are permitted: 
ï‚· MTX as specified in Section 8.5.1.   
ï‚· Oral corticosteroids at a dose of â‰¤  10 mg prednisone, or equivalent, per day are 
permitted provided they are at a stable dose for at least 4 weeks prior to 
initiation of study treatment.  The dose of oral corticosteroids may be reduced according to local guidelines during the conduct of the study. 
If at any time a subject needs additional t herapy (other than those specified in 
Section 8.5.7.3), including an increase in their MTX dose, to treat their RA, the 
Investigator should contact the Amgen Medical Monitor (or designee) to determine if the 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 33 of 77  
Confidential   subject is eligible to remain on study treatment.  If the subject is no longer eligible to 
remain on study treatment, then the subject should undergo the assessments of the week 48/EOS visit before administration of any additional therapies.  The subject should 
be withdrawn from the study treatment. 
8.5.7.2 Prohibited Concomitant Medications 
All of the following are prohibited at any time during the study: 
ï‚· Non-biologic DMARDs (other than MTX; as per exclusion criteria) including 
tofacitinib 
ï‚· Any biologic treatment for RA (eg, anakinra, soluble IL-1 type II receptor, 
etanercept, infliximab, abatacept, tociliz umab, golimumab, certolizumab, or 
adalimumab) 
ï‚· Chronic minocycline or tetracycline (except use for â‰¤ 10 days to treat infection, 
or for nonarthritis indications, eg, acne), hydroxychloroquine, mycophenolate 
mofetil, or sulfasalazine 
ï‚· Live and attenuated vaccinations are not allowed while subjects are enrolled in 
the study and receiving investigational product. 
ï‚· Any experimental (biological or nonbiological) therapy (within or outside a clinical 
study). 
ï‚· IA hyaluronic acid 
ï‚· IA, IM, or IV corticosteroids including adrenocorticotropic hormone (except of 
use as pre-medication) 
8.5.7.3 Rescue Medication 
The definition of rescue medication is any medication other than prohibited medication 
that is used to treat RA.  The use of rescue medication is allowed in this study under following conditions: 
ï‚· Oral corticosteroids:  Maximum dose allowed is 10 mg prednisone (or 
equivalent) per day; dose can be decreased if needed, per Investigatorâ€™s clinical 
judgment. 
ï‚· Acetaminophen, hydrocodone, codeine, tramadol, and/or propoxyphene may be 
used by the subject as rescue analgesics except at least 12 hours before a scheduled study efficacy evaluation (week 8, 12, 24, 40, and 48/EOS).  
ï‚· NSAIDs/cyclooxygenase-2 (COX-2) Inhibitors:  If the subject enters the study 
taking an NSAID/COX-2 inhibitor, the dose of NSAIDs/COX-2 inhibitors can be reduced or discontinued during the study if necessary for safety reasons or standard of care.  In cases of flare, the dose of NSAIDs/COX-2 inhibitors can be 
temporarily increased as needed.  However, the subject must return to the 
maintenance dose (the dose at baseline) as soon as the flare resolves.  In subjects not taking an NSAID/COX-2 inhibitor, one such treatment may be added temporarily to treat a flare in RA.  It should be tapered and discontinued with resolution of flare.  In all cases, any dose regimen higher than baseline dose is not allowed at least 12 hours before the clinical efficacy assessments 
(week 8, 12, 24, 40, and 48/EOS). 
3URGXFW$%3
&OLQLFDO6WXG\3URWRFRO'DWH0DUFK 3DJHRI 
&RQILGHQWLDOx7RSLFDODQHVWKHWLFFUHDPVHJOLGRFDLQHSULORFDLQHFUHDPVDQG OLFHQVHG16$,'
FUHDPVDUHSHUPLWWHGH[FHSWZLWKLQKRXUVEHIRUHFOLQLFDOHIILFDF\
DVVHVVPHQWVZHHNDQG(26
 3URSK\ODFWLF7UHDWPHQW
&HUWDLQ$(VDUHFRPPRQO\DVVRFLDWHGZLWK07;WUHDWPHQW,QRUGHUWRPLQLPL]H07;
WR[LFLW\VXEMHFWVPD\UHFHLYHDVWDEOHGRVHRIRUDOIRODWHRUIROLQLFDFLG7KLVFDQHLWKHUEHJLYHQDVDVLQJOHGRVHRQDZHHNO\EDVLVRUDVDGLYLGHGZHH NO\GRVHDWWKH
,QYHVWLJDWRU
VGLVFUHWLRQ
 2WKHU&RQFRPLWDQW0HGLFDWLRQVDQG7UHDWPHQWV
$Q\RWKHUWUHDWPHQWQRWH[SOLFLWO\H[FOXGHGZKLFKLVFRQVLGHU HGQHFHVVDU\IRUWKH
VXEMHFWÂ¶VZHOIDUHPD\EHJLYHQDWWKHGLVFUHWLRQRIWKH,QYHVWL JDWRU$GPLQLVWUDWLRQRI
FRQFRPLWDQWPHGLFDWLRQVPXVWEHUHFRUGHG*HQHULFQDPHVIRUFR QFRPLWDQWPHGLFDWLRQ
VKRXOGEHXVHGLISRVVLEOH
$OOVXEMHFWVZKRGLVFRQWLQXHWKHVWXG\PHGLFDWLRQVKRXOGEHRIIHUHGDOWHUQDWLYH
WUHDWPHQWLIDSSOLFDEOH7UHDWPHQWVKRXOGEHJLYHQDFFRUGLQJW RQRUPDOFOLQLFDOSUDFWLFH
DIWHUDWHUPLQDWLRQYLVLWVHH 6HFWLRQ 
 7UHDWPHQW&RPSOLDQFH
5HFRUGVRIVWXG\PHGLFDWLRQXVHGDQGLQWHUYDOVEHWZHHQYLVLWVZ LOOEHNHSWGXULQJWKH
VWXG\'UXJDFFRXQWDELOLW\ZLOOEHQRWHGE\WKHILHOGPRQLWRUGXULQJVLWHYLVLWVDQGDWWKH
FRPSOHWLRQRIWKHVWXG\7KHVWXG\WUHDWPHQWVKRXOGEHGLVSHQV HGE\WKH,QYHVWLJDWRU
RUE\DTXDOLILHGLQGLYLGXDOXQGHUWKH,QYHVWLJDWRUÂ¶VVXSHUYLVL RQ$QXSWRGDWHWUHDWPHQW
LQYHQWRU\GLVSHQVLQJUHFRUGPXVWEHPDLQWDLQHG
 $VVLJQPHQWWR7UHDWPHQW
:KHQVXEMHFWVHQWHUWKHVFUHHQLQJSHULRGIRUWKHVWXG\WKH,QY HVWLJDWRURUGHVLJQHH
ZLOOFRQWDFWWKH,;56DQGUHFHLYHDXQLTXHGLJLWVXEMHFWLGHQWLILFDWLRQQXPEHUEHIRUH
DQ\VWXG\SURFHGXUHVDUHSHUIRUPHG7KLVQXPEHUZLOOEHXVHGW RLGHQWLI\WKHVXEMHFW
WKURXJKRXWWKHFOLQLFDOVWXG\DQGPXVWEHXVHGRQDOOVWXG\GRF XPHQWDWLRQUHODWHGWRWKDW
VXEMHFW
6LJQLQJRIWKH,&)HVWDEOLVKHVHQWU\LQWRWKH
VFUHHQLQJSHULRG
7KHVXEMHFWLGHQWLILFDWLRQQXPEHUPXVWUHPDLQFRQVWDQWWKURXJKR XWWKHHQWLUHFOLQLFDO
VWXG\LWPXVWQRWEHFKDQJHGDWWKHWLPHRIUHVFUHHQLQJHQURO OPHQWRUUDQGRPL]DWLRQPPD
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 35 of 77  
Confidential   This number will not necessarily be the same  as the randomization number assigned for 
the study. 
Upon completion of screening, the Investigator (or designee) will contact the IXRS to 
randomize the subject centrally to receive either ABP 798, rituximab (US), or rituximab 
(EU) in a 1:1:1 manner.  The randomization will be stratified by geographic region, seropositivity (RF positive and/or CCP-positive vs. RF-negative and CCP-negative), and number of prior biologic therapies used for RA (1 vs. >1).  
8.5.10 Unblinding Procedures 
A subjectâ€™s treatment assignment should only be unblinded when knowledge of the treatment is essential for the further management of the subject on this study.  Unblinding at the study site for any other r eason will be considered a protocol deviation.  
The Investigator is strongly encouraged to contact the Amgen Medical Monitor (or designee) before unblinding any subjectâ€™s treatment assignment, but must do so within 
1 working day after the event. 
The identity of investigational product assigned to subject numbers or to individual boxes 
of investigational product will be available for emergency situations through the IXRS.  Authorized site staff will be provided with a unique Personal Identification Number (PIN) 
to access the IXRS to obtain unblinding information.  This PIN is unique to the individual 
and must not be shared. 
8.6 Efficacy, Pharmacokinetic/Pharm acodynamic, and Safety Variables 
8.6.1 Efficacy, Pharmacokinetic/ Pharmacodynamic, and Safety 
Measurements Assessed 
A schedule of procedures and assessments is presented in Table 1. 
8.6.1.1 Pharmacokinetic/Pharmacodynamic Endpoints 
The primary PK endpoints will be AUC inf and C max following the second infusion of the 
first dose.  Additional PK endpoints will include AUC from time 0 on day 1 prior to the 
first infusion of the first dose to 14 days postdose (day 15) (AUC 0-14 day ), AUC from time 0 
on day 1 prior to the first infusion of the first dose to week 12 (AUC 0-12 wk ), and C max 
following the first infusion of the first dose.   
PD endpoints will include the percent of subjects with complete depletion in CD19+ cell 
count from days 1 to 3.  
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 36 of 77 
Confidential   Table 1.  Schedule of Assessments and Procedures 
Study 
Visit/Day/Week 
D = Day; W = Week S 
c 
n BL/  
D1/ 
W0 D1 
EOI D1
3 h D1
6 h D
2 D
3 D15/
W2 D15
EOI D15
3 h D15
6 h D 
16 D
17 W
4 W
8 W
12 W
24aW
26 W 
30 W 
40 W48/
EOSb 
Visit Window              ï‚± 2 days   ï‚± 2 
days Â± 3 
days ï‚± 2 
days 
General Assessments                      
Informed consent 
form X                     
Medical & medication history  X                     
Physical examination  X X               X    X 
Vital signs  X X X X X   X X X X      X X X  X 
ECG  X                     
Chest radiography  Xc                     
Dosing of ABP 798/
rituximab a  Xd      Xd         Xd Xd    
Concomitant 
medication  X X X X X X X X X X X X X X X X X X X X X 
AE recording  X X X X X X X X X X X X X X X X X X X X X 
Disease Assessments                      
Tender/swollen joint count  X X             X X X   X X 
Subject and 
Investigatorâ€™s global 
health assessmente  X           
  X X X   X X 
Pain VASe  X             X X X   X X 
HAQ-DIe  X             X X X   X X 
Laboratory 
Assessments                      
Serology (HBsAg, 
anti-HBc, HCV) X                     
Serum chemistry Xf X X     X     X  X  X X  X X 
Hematology X X X     X     X  X  X X  X X 
Page 1 of 2 
See footnotes on following page.   
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 37 of 77 
Confidential   Table 1.  Schedule of Assessments and Procedures 
Study 
Visit/Day/Week 
D = Day; W = Week S 
c 
n BL/  
D1/ 
W0 D1 
EOI D1
3 h D1
6 h D
2 D
3 D15/
W2 D15
EOI D15
3 h D15
6 h D 
16 D
17 W
4 W
8 W
12 W
24aW
26 W 
30 W 
40 W48/
EOSb
Visit Window              ï‚± 2 days   ï‚± 2 
days ï‚± 3 
daysï‚± 2 
days 
Laboratory 
Assessments ( contâ€™d)                      
CRP Xg X             X X X   X X 
ESR Xg                     
PK sampling h  X X X X X X X X X X X X X X X X X X  X 
Antidrug antibodies  X      X         X  X  X 
CD19+ cell count  X    X X       X   X    X 
IgA, IgG, and IgM 
levels  X    Xi Xi       X   X    X 
Urinalysis X X      X         X    X 
Tuberculosis testing X                     
Pregnancyj X X      X       X  X   X X 
Anti-CCP X                     
Rheumatoid factor X                     
Page 2 of 2 
AE = adverse event; BL = Baseline; CRP = C-Reactive Protein; EOI = End of Infusion; EOS = End of Study; ESR = Erythrocyte sedim entation rate; h = hour; HAQ-DI = 
Health Assessment Questionnaire â€“ Disabilit y Index; HBsAg = Hepatitis B surface antigen; Anti-HBc = Hepatitis B core antibody; HCV = Hepatitis C virus antibody; Ig = 
Immunoglobulin, PK = Pharmacokinetic; Scn = Screening; VAS = Vis ual analogue scale; Anti-CCP= Anti-cyclic citrullinated peptide  antibody 
a The second dose will be administered at week 24 or earlier, ie, an ytime from week 16 to week 24, in individual subjects, if ne cessary in the opinion of the 
Investigator.  For subjects who receive retreatment before week  24, all week 24 and post-week-24 assessments will be moved up t o the corresponding time point 
after treatment (eg, week 26 will be 2 weeks after retreatment, week 30 will be 6 weeks after retreatment, etc.).  An infusion may be delayed up to 7 days to allow for 
recovery from infection. 
b Subjects early terminating study should perform week 48 procedures.  
c Historical radiograph performed within 3 months prior to first dose of IP may be used and does not need to be repeated at scre ening (section 10.7 for details) 
d ABP 798/rituximab dosing to be administered after all other procedures are completed for each visit.  
e Subjective assessments will be the first procedures performed at the visit. 
f Includes any other lab tests required only for screening.  Cr eatinine clearance calculation will be performed only at screenin g. 
g Either CRP or ESR is required at screening.  CRP will be perform ed by central lab and results will be blinded to study sites.  ESR will be performed by local 
laboratory. 
h PK sampling: day 1, predose, at EOI, and 3 and 6 hours postdose; day 2 (24 hours postdo se); day 3 (48 hours postdose); day 15, predose, at EOI, and 3, 6, and 24 
hours postdose (day 16), and 48 hours postdose (day 17).  In addition, at week 4 (day 29), week 8 (day 57), week 12 (day 85), a nd predose week 24, week 26, and 
week 30, 48/EOS.  Blood sampling for PK analysis during each return  visit, including the EOS visit, will occur per the schedule d time point with tolerance collection 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 38 of 77 
Confidential   windows as follows:  Day 1 predose = within 1 hour prior to dosing; days 1 and 15 at EOI = infusion should be monitored to ensu re collection of the PK sample within 
10 minutes after the end of the infusion; all other Day 1 samplin g times = Â± 10 minutes; days 2 and 3 = Â± 3 hours; predose Day 15 = within 1 hour prior to dosing; all 
other Day 15 sampling time = Â± 10 minutes; days 16 and 17 = Â± 3 hours; week 4, 8 and 12 =  Â± 2 days; predose at weeks 24 and 26  = within 1 hour prior to dosing; 
and weeks 30 and 48 = Â± 2 days. 
i Only IgM required on Days 2 and 3. 
j Pregnancy test for females of child-bearing potential.  Seru m pregnancy test will be done at screening by the central laborator y.  Urine pregnancy test performed 
locally at subsequent time points. 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 39 of 77 
Confidential   8.6.1.2 Efficacy Measurements 
8.6.1.2.1 Efficacy Criteria 
Efficacy is a secondary objective in this study.  The efficacy endpoint is Disease Activity 
Score (DAS) 28-CRP change from baseline at week 24.  The endpoint will also be assessed at weeks 8, 12, 40, and 48.   
In addition, ACR20 (20% improvement in A CR core set measurements), ACR50 (at least 
50% improvement compared to baseline)  and ACR70 (at least 70% improvement 
compared to baseline) will also be assessed at weeks 8, 12, 24, 40, and 48.  
DAS28-CRP  
The DAS28-CRP is a continuous measure based on 28 DAS joints from the ACR 
(indicated with * in Section 17.3), the Subject's Global Health Assessment score (as 
assessed as a score of 0 to 100 transformed from the results on a 100-mm VAS scale), and CRP, as follows:  
DAS28-CRP = 0.56*(TJC28)0.5 + 0.28*(SJC28) 0.5 + 0.36*ln(CRP+1) + 0.014*GH + 0.96  
where TJC28 is the tender joint count of the 28 joints in the DAS, SJC28 is the 28 swollen joint count, CRP is in mg/L, and GH is the Subject's Global Health Assessment in 0 to 100 scale ( van Gestel et al, 1998 ).  
ACR 
Improvement compared to baseline is requi red for both swollen and tender joint counts 
(66/68 joint counts; Section 17.3), as well as for 3 out of the following 5 additional 
parameters:  
ï‚· Subject's Global Health Assessment (on a 100-mm visual analogue scale [VAS]; 
Section 17.4 ) 
ï‚· Investigator's Global Health Assessment (on a 100-mm VAS; Section 17.4) 
ï‚· Subject's assessment of pain (on a 100-mm VAS; Section 17.4) 
ï‚· Health Assessment Questionnaire â€“ Disability Index (HAQ-DI; Section 17.4) 
ï‚· CRP  
8.6.1.3 Safety Measurements 
Safety endpoints include the following: 
ï‚· treatment-emergent AEs and serious adverse events (SAEs) 
ï‚· clinically significant changes in laboratory values and vital signs  
ï‚· incidence of antidrug antibodies 
 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 40 of 77 
Confidential   9 STUDY EVALUATIONS BY VISIT 
After signing the informed consent, there are 15 visits, including a screening visit and 
visits on days 1, 2, 3, 15, 16, and 17 and weeks 4, 8, 12, 24, 26, 30, 40, and 48/EOS.  After the first 18 subjects have received at least 1 dose of investigational product (ie, 
infusions on days 1 and 15) an initial safety  analysis will be conducted by the DMC.   
9.1 Screening 
After subjects have provided informed consent, the following assessments/procedures 
will be performed within the 28 day screening period: 
ï‚· targeted medical history, including history of all prior treatments for RA within the 
past 3 years and any prior biologic therapies used for RA 
ï‚· physical examination, including eval uation of body systems and height and 
weight 
ï‚· vital signs (systolic and diastolic blood pressure, pulse, respiration rate, and 
temperature)  
ï‚· standard 12-lead electrocardiogram (ECG) 
ï‚· chest radiography (prior radiography or fo rmal reports signed off by a radiologist 
within 3 months of first dose of investigational product is acceptable) 
ï‚· screening joint assessments (DAS and ACR tender/swollen joint counts; 
Section 17.3 )  
ï‚· tuberculosis testing (PPD or Quantiferon test)  
ï‚· clinical laboratory testing, including serology, serum chemistry, hematology, 
either CRP or ESR, anti-CCP, and rheumatoid factor.  
ï‚· collection of samples for urinalysis 
ï‚· serum pregnancy test for women of childbearing potential 
At the screening assessment, all concomitant  medications from 3 months before the 
planned start of study treatment, all prior treatments for RA within the past 3 years and any prior biologic therapies used for RA will be recorded.  Any AEs occurring during the 
screening period will be recorded as medical history; any SAEs will be recorded using 
the eCRF.  SAEs will be reported as outlined in Section 11.2.2. 
Subjects will continue on their stable pre-study MTX regimen during the screening period. 
9.1.1 Screen Failures 
Subjects determined to be screen failures will not be eligible for immediate participation 
and must be registered as a screen failure in IXRS.  Laboratory assessments used to 
determine subject eligibility may be repeated during the screening period before the subject is considered a screen failure.  Screen failed subjects may be re-screened up to 2 times at the Investigatorâ€™s discretion (ie, a total of 3 screens including initial screening).  
The subject will retain the same subject ID number provided at the initial screening.  
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 41 of 77 
Confidential   Subjects must be re-consented if more than 30 days have elapsed between date of 
initial informed consent and date of re-screen/randomization.  
9.2 Baseline (Day 1, first day of treatment, Week 0) 
Day 1 will be defined as the first day of treatment.  After subjects are confirmed to meet 
the entry criteria (Section 8.4), the Investigator (or designee) will contact the IXRS to 
randomize the subject centrally to receive either ABP 798, rituximab (US), or rituximab 
(EU).  The following assessments/procedures will be performed before treatment: 
ï‚· subjective assessments (Subject's Global Health Assessment, subject's 
assessment of pain, and HAQ-DI, Section 17.4); subjective assessments will be 
the first assessments performed at the visit 
ï‚· physical examination, including evaluation of body systems  
ï‚· vital signs (systolic and diastolic blood pressure, pulse, respiration rate, and 
temperature) 
ï‚· baseline joint assessments (DAS and  ACR tender/swollen joint counts; 
Section 17.3 )  
ï‚· Investigator's Global Health Assessment 
ï‚· clinical laboratory testing, including serum chemistry, hematology, and CRP 
ï‚· urinalysis and urine pregnancy test (for women of childbearing potential) 
ï‚· collection of pretreatment PK samples  (within 1 hour predose) and samples for 
pretreatment antidrug antibodies, CD19+ cell count, and IgA, IgG, and IgM levels 
Any changes in concomitant medications since the last assessment will be recorded.  
Any pretreatment AEs will be recorded as medical history; any pretreatment SAEs will be recorded using the eCRF.  SAEs will be reported as outlined in Section 11.2.2. 
After completion of pretreatment procedures, ABP 798, rituximab (US), or rituximab (EU) will be administered as an IV infusion in a double-blinded fashion.  Starting at the time of 
first treatment, all AEs, including increases in severity or frequency of pre-existing 
conditions, will be recorded in the eCRF.  
At the end of infusion (EOI), blood samples for serum chemistry and hematology will be drawn.  
At EOI and 3 and 6 hours after EOI, the following assessments will be performed: 
ï‚· vital signs (systolic and diastolic blood pressure, pulse, respiration rate, and 
temperature)  
ï‚· collection of PK samples (within 10 minutes after the end of the infusion, 
Â± 10 minutes at 3 and 6 hours) 
Subjects may leave the site after the 6-hour post-EOI assessment.  Subjects will 
continue on their stable MTX regimen.   
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 42 of 77 
Confidential   9.3 Day 2 
On day 2, approximately 24 hours after EOI, a PK sample ( Â± 3 hours) and samples for 
CD19+ cell count and IgM levels will be collected.  Subjects will continue on their stable 
MTX regimen.   
Any changes in concomitant medications since the last assessment will be recorded.  All 
AEs, including increases in severity or frequency of pre-existing conditions, will be 
recorded.  SAEs will be reported as outlined in Section 11.2.2 .   
9.4 Day 3 
Two days (approximately 48 hours after EOI) a fter the first infusion, the subject will 
return to the study site for collection of samples PK (Â±  3 hours), CD19+ cell count, and 
IgM levels.   
Any changes in concomitant medications since the last assessment will be recorded.  All 
AEs, including increases in severity or frequency of pre-existing conditions, will be recorded.  SAEs will be reported as outlined in Section 11.2.2 .   
9.5 Day 15 (Week 2) 
Two weeks after the first infusion, the subject will return to the study site for the second infusion.  Subjects will remain at the site for 6 hours post-treatment for sample collection.  
The following assessments/procedures will be performed before the infusion on day 15: 
ï‚· vital signs (systolic and diastolic blood pressure, pulse, respiration rate, and 
temperature) 
ï‚· clinical laboratory testing, including serum chemistry and hematology 
ï‚· urinalysis and urine pregnancy test (for women of childbearing potential) 
ï‚· collection of pretreatment PK samples (within 1 hour predose) and samples for 
antidrug antibodies 
Any changes in concomitant medications since the last assessment will be recorded.  All 
AEs, including increases in severity or frequency of pre-existing conditions, will be 
recorded in the eCRF.  SAEs will be reported as outlined in Section 11.2.2. 
After completion of pretreatment procedures, ABP 798, rituximab (US), or rituximab (EU) 
will be administered as an IV infusion in a double-blinded fashion.   
At the EOI and 3 and 6 hours after EOI, t he following assessments will be performed: 
ï‚· vital signs (systolic and diastolic blood pressure, pulse, respiration rate, and 
temperature)  
ï‚· collection of PK samples (within 10 minutes after the end of the infusion, 
Â± 10 minutes at 3 and 6 hours) 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 43 of 77 
Confidential   Any changes in concomitant medications since the last assessment will be recorded.  All 
AEs, including increases in severity or frequency of pre-existing conditions, will be recorded in the eCRF.  SAEs will be reported as outlined in Section 11.2.2.  
Subjects may leave the site after the 6-hour post-EOI assessment. 
9.6 Day 16 
On day 16, approximately 24 hours ( Â± 3 hours) after completing the second infusion, a 
PK sample will be collected.  Subjects will continue on their stable MTX regimen.   
Any changes in concomitant medications since the last assessment will be recorded.  All 
AEs, including increases in severity or frequency of pre-existing conditions, will be 
recorded.  SAEs will be reported as outlined in Section 11.2.2.   
9.7 Day 17 
On day 17, approximately 48 hours (Â± 3 hours) after the second infusion, the subject will 
return to the study site for collection of samples for serum chemistry, hematology, and PK.  
Any changes in concomitant medications since the last assessment will be recorded.  All 
AEs, including increases in severity or frequency of pre-existing conditions, will be 
recorded.  SAEs will be reported as outlined in Section 11.2.2 .   
9.8 Week 4 (ï‚±  2 days) 
Four weeks ( ï‚± 2 days) after the first infusion, the subject will return to the study site.  The 
following assessments/procedures will be performed at week 4: 
ï‚· collection of PK samples and samples for CD19+ cell count and IgA, IgG, and 
IgM levels 
Any changes in concomitant medications since the last assessment will be recorded.  All AEs, including increases in severity or frequency of pre-existing conditions, will be 
recorded in the eCRF.  SAEs will be reported as outlined in Section 11.2.2.   
9.9 Week 8 (ï‚±  2 days) 
Eight weeks ( ï‚± 2 days) after the first infusion, the subject will return to the study site.  
The following assessments/procedures will be performed at week 8: 
ï‚· joint assessments (DAS and ACR tender/swollen joint counts; Section 17.3)  
ï‚· subjective assessments (Subject's Global Health Assessment, subject's 
assessment of pain, and HAQ-DI, Section 17.4); subjective assessments will be 
the first assessments performed at the visit 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 44 of 77 
Confidential   ï‚· Investigator's Global Health Assessment 
ï‚· clinical laboratory testing, including serum chemistry, hematology, and CRP 
ï‚· collection of PK samples  
ï‚· urine pregnancy test (for women of childbearing potential) 
Any changes in concomitant medications since the last assessment will be recorded.  All 
AEs, including increases in severity or frequency of pre-existing conditions, will be recorded in the eCRF.  SAEs will be reported as outlined in Section 11.2.2.   
9.10 Week 12 ( ï‚± 2 days) 
Twelve weeks ( ï‚± 2 days) after the first infusion, the subject will return to the study site for 
safety and efficacy assessment.  The following assessments/procedures will be 
performed at week 12: 
ï‚· subjective assessments (Subject's Global Health Assessment, subject's 
assessment of pain, and HAQ-DI, Section 17.4); subjective assessments will be 
the first assessments performed at the visit 
ï‚· joint assessments (DAS and  ACR tender/swollen joint counts; Section 17.3)  
ï‚· Investigator's Global Health Assessment 
ï‚· clinical laboratory testing including CRP 
ï‚· collection of PK samples 
Any changes in concomitant medications since the last assessment will be recorded.  All 
AEs, including increases in severity or frequency of pre-existing conditions, will be 
recorded in the eCRF.  SAEs will be reported as outlined in Section 11.2.2.   
9.11 Week 24  
Twenty-four weeks after the first infusion (or at the time of retreatment if required before 
week 24), the subject will return to the study site for assessment and treatment.  The following assessments/procedures will be per formed before treatment at week 24: 
ï‚· subjective assessments (Subject's Global Health Assessment, subject's 
assessment of pain, and HAQ-DI; Section 17.4); subjective assessments will be 
the first assessments performed at the visit 
ï‚· physical examination, includi ng evaluation of body systems 
ï‚· vital signs (systolic and diastolic blood pressure, pulse, respiration rate, and 
temperature)  
ï‚· joint assessments (DAS and  ACR tender/swollen joint counts; Section 17.3)  
ï‚· Investigator's Global Health Assessment 
ï‚· clinical laboratory testing, including serum chemistry, hematology, and CRP 
ï‚· urinalysis and urine pregnancy test (for women of childbearing potential) 
ï‚· collection of pretreatment PK samples (within 1 hour predose) and samples for 
antidrug antibodies, CD19+ cell count, and IgA, IgG, and IgM levels 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 45 of 77 
Confidential   Any changes in concomitant medications since the last assessment will be recorded.  All 
AEs, including increases in severity or frequency of pre-existing conditions, will be recorded in the eCRF.  SAEs will be reported as outlined in Section 11.2.2. 
After completion of pretreatment procedures, ABP 798 or rituximab (EU) will be administered as an IV infusion in a double-blinded fashion.  Subjects who had previously received rituximab (US) will be transitioned to ABP 798, but this change will be managed by the IXRS to maintain the blind.  Subjects will continue on their stable MTX regimen.   
9.12 Week 26  
Twenty-six weeks after the first infusion (or 2 weeks after initiation of retreatment if retreatment occurred before week 24), the subject will return to the study site for assessment and treatment.  The following a ssessments/procedures will be performed 
before treatment at week 26: 
ï‚· vital signs (systolic and diastolic blood pressure, pulse, respiration rate, and 
temperature)  
ï‚· clinical laboratory testing, including serum chemistry and hematology 
ï‚· collection of pretreatment PK samples (within 1 hour predose) 
After completion of pretreatment procedures, ABP 798 or rituximab (EU) will be administered as an IV infusion in a double-blinded fashion.  Any changes in concomitant medications since the last assessment will be recorded.  All AEs, including increases in severity or frequency of pre-existing conditions, will be recorded in the eCRF  and will be 
reported as outlined in Section 11.2.2.  Subjects will continue on their stable MTX 
regimen.   
9.13 Week 30 ( ï‚± 2 days) 
Thirty weeks ( Â± 2 days) after the first infusion (or 6 weeks after initiation of retreatment if 
retreatment occurred before week 24), the subject will return to the study site.  The following assessments/procedures will be performed at week 30: 
ï‚· vital signs (systolic and diastolic blood pressure, pulse, respiration rate, and 
temperature)  
ï‚· collection of PK samples and samples for antidrug antibodies  
Any changes in concomitant medications since the last assessment will be recorded.  All AEs, including increases in severity or frequency of pre-existing conditions, will be recorded in the eCRF.  SAEs will be reported as outlined in Section 11.2.2. 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 46 of 77 
Confidential   9.14 Week 40 ( ï‚± 3 days)  
Forty weeks ( ï‚± 3 days) after the first infusion (or 16 weeks after initiation of retreatment if 
retreatment occurred before week 24), the subject will return to the study site.  The 
following assessments/procedures will be performed at week 40: 
ï‚· subjective assessments (Subject's Global Health Assessment, subject's 
assessment of pain, and HAQ-DI, Section 17.4); subjective assessments will be 
the first assessments performed at the visit 
ï‚· joint assessments (DAS and  ACR tender/swollen joint counts; Section 17.3)  
ï‚· Investigator's Global Health Assessment 
ï‚· clinical laboratory testing, including serum chemistry, hematology, and CRP 
ï‚· urine pregnancy test (for women of childbearing potential) 
Any changes in concomitant medications since the last assessment will be recorded.  All 
AEs, including increases in severity or frequency of pre-existing conditions, will be recorded in the eCRF.  SAEs will be reported as outlined in Section 11.2.2. 
9.15 Week 48 (EOS) 
Forty-eight weeks ( ï€ ï‚± 2 days) after the first infusion (or 24 weeks after initiation of 
retreatment if retreatment occurred before week 24) or at the time of early 
discontinuation, the subject will return to the study site for a follow-up assessment.  The 
following assessments/procedures will be performed at week 48/EOS: 
ï‚· subjective assessments (Subject's Global Health Assessment, subject's 
assessment of pain, and HAQ-DI; Section 17.4); subjective assessments will be 
the first assessments performed at the visit 
ï‚· Investigator's Global Health Assessment 
ï‚· physical examination, includi ng evaluation of body systems 
ï‚· vital signs (systolic and diastolic blood pressure, pulse, respiration rate, and 
temperature)  
ï‚· joint assessments (DAS and ACR tender/swollen joint counts; Section 17.3)  
ï‚· clinical laboratory testing, including serum chemistry, hematology, and CRP 
ï‚· urinalysis and urine pregnancy (for women of childbearing potential) 
ï‚· collection of PK samples (PK sample must be within 2 days of week 48) and 
samples for antidrug antibodies, CD19+ cell count, and IgA, IgG, and IgM levels 
Any changes in concomitant medications since the last assessment will be recorded. All 
AEs, including increases in severity or frequency of pre-existing conditions, will be recorded in the eCRF through the week 48/EOS visit.  SAEs will be reported as outlined in Section 11.2.2.  Any SAEs ongoing at week 48/EOS will be followed until they resolve 
or are considered chronic or stable. 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 47 of 77 
Confidential   10 METHODS OF ASSESSMENT 
10.1 Rheumatoid Arthritis Assessments 
At each time point for RA assessments, the Subject's Global Health Assessment, 
subject's assessment of pain, and HAQ-DI (Section 17.4) will be completed.  These 
assessments should be the first assessments performed at the visits at which they are 
scheduled.   
At these same time points, joints will be assessed and classified as swollen/not swollen 
and tender/not tender by pressure and joint manipulation on physical examination.  Joint prosthesis, arthrodesis, or fused joints will not be assessed for swelling or tenderness.  
The joints to be assessed for swelling and tenderness are given in Section 17.3, 
including the 28 joint-count for DAS and the 66/68 joint set for ACR.  All joint 
assessments will be performed by an experienc ed joint evaluator.  The evaluator cannot 
be the treating physician and cannot interact with the subject on the study beyond the assessment of joints.  The evaluator should not discuss the subjectâ€™s clinical status, nor 
should the evaluator have access to subject medical records or eCRFs, including prior 
joint assessments.  The same evaluator should perform joint assessments across all time points for a subject where possible. 
For the screening and baseline joint counts, the distal interphalanges should be 
evaluated, but should not be included in the total joint count to determine eligibility. 
The Investigator's Global Health Assessment will also be completed at the times 
indicated in Table 1.  The independent joint assessor may not complete the 
Investigatorâ€™s Global Disease Assessment.  The physician completing the Investigatorâ€™s Global Disease Assessment will have access to the joint assessments.  The subject and 
physician must complete the global assessments independently from each other. 
10.2 Pregnancy Test 
Pregnancy will be determined by evaluation of ï¢-human chorionic gonadotrophin 
(ï¢-HCG) in serum at screening by central laboratory and in urine at subsequent time 
points locally for all women of childbearing potential.  Subjects who are pregnant are 
excluded from the study. 
The Investigator will inform the Sponsor immediately of any case of pregnancy and 
collect information on any female subject who becomes pregnant while participating in 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 48 of 77 
Confidential   this study and in case of pregnancy among female partners of male subjects.  The 
subject will also be followed to determine the outcome of the pregnancy. 
10.3 Physical Examination  
Physical examinations will be performed by a physician and will include examination of 
the following:  general appearance, head, ears, eyes, nose, throat, neck, skin, cardiovascular system, respiratory system, abdominal system and nervous system.  For 
each body system an assessment of normal or  abnormal will be recorded.  Clinically 
relevant changes from baseline will be reported as AEs. 
Body weight (kg) will be measured without shoes or jacket.  Height will be determined at 
screening. 
10.4 Vital Signs  
Systolic blood pressure and diastolic blood pressure will be measured on the same arm (preferentially on the left arm) after the subject has been in a supine/sitting position for 5 minutes.  Pulse will be recorded simultaneously with blood pressure measurements.  
Respiration rate and temperature will also be recorded. 
During the study, measurement of vital signs may be repeated at the discretion of the 
Investigator for safety reasons.  Clinically relevant abnormal findings will be reported as AEs. 
10.5 Electrocardiogram 
Computerized 12-lead ECG recordings will be obtained after the subject has been supine for 5 minutes.  Each lead will be recorded for at least 3 to 5 beats at a speed of 25 mm/sec paper speed and 10 mm/mV amplitude.  At a minimum, heart rate, P, PR, QRS, and QT will be recorded from the 12-lead ECG.  A copy of the ECGs will be retained on site.  For the purposes of screening, the Investigator or a designee will 
evaluate whether the ECG is normal or abnormal and whether it is clinically acceptable 
for inclusion, if abnormal.   
10.6 Tuberculosis Testing 
A tuberculosis test will be performed at screening by PPD or Quantiferon test.  PPD tests will be performed locally, and Quantiferon tests will be performed by the central or 
local laboratory.  Subjects with positive PPD/Quantiferon test may be eligible based on 
the Sponsorâ€™s tuberculosis risk assessment wo rksheet and the other criteria listed in 
Inclusion Criterion 13. 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 49 of 77 
Confidential   10.7 Chest Radiography  
Chest radiography will be performed at screening as indicated in Table 1  and will include 
anterior/posterior or posterior/anterior and lateral views.  Chest x-ray performed at the 
site can be read by the Investigator.  A formal report, signed off by the Investigator, 
should be filed in subjectâ€™s medical records.  If the x-ray is performed off site, then formal 
reports signed off by a radiologist should be acceptable.  Historical films obtained, or formal reports signed off by a radiologist within the 3 months prior to receiving investigational product are acceptable for screening as well. 
10.8 Clinical Laboratory Testing 
Venous blood samples will be taken for clinical laboratory tests at the time points indicated in Table 1.  The following parameters will be determined: 
Serology:  HbsAg, anti-HBc, and HCV antibody 
Hematology:   Hemoglobin, hematocrit or packed cell volume, red blood cell count, 
mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, white blood 
cell count and differential, platelet count. 
Clinical chemistry:  Sodium, potassium, urea, creatinine, total protein, albumin, total 
bilirubin, AST, ALT, alkaline phosphatase, gamma glutamyl transferase, nonfasting glucose, phosphate, and uric acid.  Rheumatoid Factor and anti-CCP will be assessed at 
screening.  CRP will be assessed at the time points indicated in Table 1 .  CRP results 
from the baseline visit and onwards will be blinded  to study sites and not included in the 
central laboratory report to the site. 
Urinalysis (fresh urine):   pH, protein, glucose, bilirubin, blood. 
Immunology:  Blood samples for antidrug antibody assessments will be collected at the 
time points indicated in Table 1. 
The above clinical laboratory tests will be sent to and assessed at a central laboratory, 
except urine pregnancy, which will be assessed locally, and immunology, which will be sent to central laboratory and analyzed by Amgen or a designee.  Further details of the 
procedures to be followed for sample collection, storage, and shipment will be 
documented in a Laboratory Manual. 
Samples testing positive for binding antibodies will also be tested for neutralizing 
antibodies and may be further characterized for quantity/titer, isotype, affinity, and 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 50 of 77 
Confidential   presence of immune complexes.  Additional blood samples may be obtained to rule out 
antidrug antibodies during the study. 
Additional and repeat laboratory safety testing may be performed at the discretion of the 
Investigator.  Any clinically relevant c hanges from baseline will be reported as AEs. 
IgA, IgG, and IgM levels will also be collected, as indicated in Table 1.  
10.9 Blood Samples for Pha rmacokinetic Analysis  
During treatment, a series of serum samples will be taken according to Table 1 .  The 
exact times of blood sampling will be recorded.  
Blood sampling for PK analysis during each return visit, including the EOS visit, will 
occur per the scheduled time point with tolerance collection windows as follows: 
ï‚· predose day 1 = within 1 hour prior to dosing  
ï‚· days 1 and 15 at EOI - infusion should be monitored to ensure collection of the 
PK sample within 10 minutes after the end of the infusion 
ï‚· all other day 1 sampling times = Â± 10 minutes 
ï‚· days 2 and 3 = Â± 3 hours 
ï‚· predose day 15 = within 1 hour prior to dosing 
ï‚· all other day 15 sampling time = Â± 10 minutes 
ï‚· days 16 and 17 = Â± 3 hours 
ï‚· weeks 4, 8, and 12 = Â± 2 days 
ï‚· predose at weeks 24 and 26 = within 1 hour prior to dosing 
ï‚· weeks 30 and 48 = Â± 2 days 
Details of the procedures to be followed for sample collection, storage, and shipment will 
be documented in the Laboratory Manual. 
10.10 Blood Samples for Pha rmacodynamic Analysis 
Pharmacodynamic analyses will include CD19+ cell count.  Samples will be collected at 
the time points indicated in Table 1.   
Details of the procedures to be followed for sample collection, storage, and shipment will 
be documented in the Laboratory Manual. 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 51 of 77 
Confidential   11 SAFETY DATA COLLECTION, RECORDING, AND REPORTING 
11.1 Adverse Events 
11.1.1 Definition of  Adverse Events 
An AE is defined as any untoward medical occurrence in a clinical trial subject.  The 
event does not necessarily have a causal relationship with study treatment.  The Investigator is responsible for ensuring that any AEs observed by the Investigator or 
reported by the subject are recorded in the subjectâ€™s medical record as well as the 
eCRF.   
The definition of AEs includes worsening of a pre-existing medical condition.  Worsening 
indicates that the pre-existing medical condition (eg, diabetes, migraine headaches, 
gout) has increased in severity, frequency, and/or duration, and/or has an association 
with a significantly worse outcome.  In the case of worsening of a pre-existing condition, the start date of the event is the date when the first signs of worsening were observed.  A pre-existing condition that has not worsened during the study or involves an intervention such as elective cosmetic sur gery or a medical procedure while on study is 
not considered an AE.   
11.1.2 Reporting Procedures for Adverse Events 
The Investigator is responsible for ensuring that all AEs observed by the Investigator or reported by the subject that occur from the day of randomization until the week 48 visit (or through 28 days after the last dose of investigational product for subjects who discontinue study early) are reported using the applicable eCRF Adverse Event 
Summary page.  AEs observed by the Investigat or or reported by the subject that occur 
after signing of informed consent but before randomization will  be recorded.  
The Investigator must assign the following AE attributes: 
ï‚· AE diagnosis or syndrome(s), if known (if not known, signs or symptoms) 
ï‚· dates of onset and resolution 
ï‚· severity  
ï‚· assessment of relatedness to IP  
ï‚· action taken 
AEs must be graded for severity according to the National Cancer Institute (US) 
Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 
(http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ ctc.htm).   
The Investigator must assess whether the AE is possibly related to the investigational 
product.  This relationship is indicated by a â€œyesâ€ or â€œnoâ€ response to the question:  â€œIs 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 52 of 77 
Confidential   there a reasonable possibility that the event may have been caused by the 
investigational product?â€ 
The Investigator is responsible for reviewing laboratory test results and determining 
whether an abnormal value in an individual study subject represents a clinically 
significant change from the subjectâ€™s baseline values.  In general, abnormal laboratory findings without clinical significance (based on the Investigator's judgment) are not to be recorded as AEs.  However, laboratory value changes that require treatment or 
adjustment in current therapy are considered AEs.  Where applicable, clinical sequelae 
(not the laboratory abnormality) are to be recorded as the AE. 
The Investigatorâ€™s clinical judgment is used to determine whether a subject is to be 
removed from treatment due to an AE.  A subject, or subjectâ€™s legal guardian, can also voluntarily withdraw from treatment due to an AE.  If the subject withdraws consent, the 
subject is encouraged to undergo, at a minimum, an EOS assessment.   
11.2 Serious Adverse Events 
11.2.1 Definition of Se rious Adverse Events 
An SAE is defined as an AE that meets at least 1 of the following serious criteria: 
ï‚· fatal 
ï‚· life-threatening (places the subject at immediate risk of death) 
ï‚· requires inpatient hospitalization or prolongation of existing hospitalization 
ï‚· results in persistent or significant disability/incapacity 
ï‚· congenital anomaly/birth defect 
ï‚· other medically important serious event 
An AE would meet the criterion of â€œrequires hospitalizationâ€, if the event necessitated an 
admission to a health care facility (eg, overnight stay).   
If an Investigator considers an event to be clin ically important, but it does not meet any 
of the serious criteria, the event could be cl assified as a SAE under the criterion of â€œother 
medically important serious event.â€  Examples of such events could include allergic 
bronchospasm, convulsions, blood dyscrasias, drug induced liver injury, or events that 
necessitate an emergency room visit, outpatient surgery, or urgent intervention. 
11.2.2 Reporting Procedures for Serious Adverse Events 
The Investigator is responsible for ensuring that all SAEs observed by the Investigator or reported by the subject that occur after signing of the ICF through the week 48 visit (or 28 days after the last dose of investigational product for subjects who discontinue early) are recorded in the subjectâ€™s medical record and are submitted to Amgen.   
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 53 of 77 
Confidential   The SAE must be submitted to Amgen, or its designee, within 24 hours following the 
Investigatorâ€™s knowledge of the event via the applicable eCRF.   
If the electronic data capture (EDC) system is not functional, the SAE can be reported by 
faxing a completed paper SAE Fax Cover Sheet and SAE report form or by direct 
telephone communication with PRA Safety Risk Management at the numbers provided below.  The event must be updated electronically in EDC by the clinical site once the EDC function resumes. 
Fax information to Safety Risk Management/ PRA, for the attention of:  
PRA Drug Safety Center 
For Europe, Asia, and Pacific Region Clinical Sites: 
FAX:  +44 1792 525 720 Phone:  +49.621.8782.154 CHOSafety@praintl.com 
For North America, Latin America, and South America Clinical Sites: 
FAX:  1.888.772.6919 Phone:  1.800.772.2215 CHOSafety@praintl.com 
New information relating to a previously reported SAE must be submitted to Amgen, or 
its designee.  All new information for SAEs must be sent to Amgen, or its designee, within 24 hours following knowledge of the new information.  The Investigator may be 
asked to provide additional follow-up information, which may include a discharge 
summary or extracts from the medical reco rd.  Information provided about the SAE must 
be consistent with that recorded on the applicable eCRF (eg, AE Summary eCRF). 
Elective hospitalizations are not considered SAEs.  If a subject is permanently withdrawn 
from protocol-required therapies because of a SAE, this information must be submitted 
to Amgen, or its designee. 
To comply with worldwide reporting regulations for SAEs, the treatment assignment of 
subjects who develop serious, unexpected, and related AEs may be unblinded by Amgen, or its designee, before submission to regulatory authorities.  Investigators will 
receive notification of related SAE reports sent to regulatory authorities in accordance 
with local requirements.   
Determination of expectedness for Amgen products will be based on the contents of the 
Investigatorâ€™s Brochure for investigational products and the regional prescribing 
information for products being studied for an approved use.  Expectedness assessments 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 54 of 77 
Confidential   are to be made for all investigational products (Amgen and non-Amgen) using the 
appropriate reference safety information per local regulatory reporting requirements.  Suspected unexpected serious adverse reactions (SUSARs) reported for subjects 
receiving a non-Amgen investigational products are to be expedited according to local 
requirements.  
Amgen, or its designee, reports SAEs and/or SUSARs as required to regulatory 
authorities, Investigators/institutions, and IRBs/IECs in compliance with all reporting 
requirements according to local regulations and GCPs.  
The Investigator is to notify the appropriate IRB/IEC of SAEs occurring at the site and 
other AE reports received from Amgen, in accordance with local procedures and statutes. 
After the protocol-required reporting period defined above, the Investigator does not 
need to actively monitor subjects for SAEs.  However, if the Investigator becomes aware 
of an SAE after this protocol-required reporting period, the Investigator will report the event to Amgen within 24 hours following the Investigatorâ€™s knowledge of the event.  SAEs reported outside of the protocol-required reporting period will be captured within 
the safety database as clinical trial cases for the purposes of expedited reporting.   
11.3 Adverse Events of Special Interest 
AEs of Special Interest for ABP 798/rituximab will be defined in the Statistical Analysis 
Plan (SAP) and analyzed from the clinical database.  There are no expedited reporting requirements for AEs of Special Interest (other than those that meet other reporting requirements). 
11.4 Pregnancy Reporting 
Pregnancy in itself is not regarded as an AE unless there is a suspicion that an investigational product may have interfered with the effectiveness of a contraceptive medication.  However, the outcome of all pregnancies (spontaneous miscarriage, elective termination, normal birth, or congenital abnormality) must be followed up and 
documented even if the subject was discontinued from the study. 
All reports of congenital abnormalities/birth defects are SAEs.  Spontaneous 
miscarriages should also be reported and handled as SAEs.  Elective abortions without complications should not be handled as AEs.  All outcomes of pregnancy must be reported to Amgen, or its designee. 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 55 of 77 
Confidential   Pregnancies among female partners of male subjects will also be reported and followed 
for outcome. 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 56 of 77 
Confidential   12 DATA MANAGEMENT AND ST ATISTICAL ANALYSIS 
The data management and statistical analysis of this study will be performed by an 
external clinical research organization (CRO) PRA. 
12.1 Data Management 
Previous and concomitant medications will be coded using the latest available World 
Health Organization (WHO) Drug Reference Di ctionary.  Coexistent diseases and AEs 
will be coded using MedDRA (Medical Dictionary for Regulatory Activities). 
When the database has been declared to be complete and accurate, it will be locked. 
12.2 Sample Size Estimation 
Approximately 300 subjects will be randomized in a 1:1:1 ratio to receive ABP 798, 
rituximab (US), or rituximab (EU), stratified by geographic region, seropositivity 
(RF-positive and/or CCP-positive vs. RF -negative and CCP-negative), and number of 
prior biologic  therapies used for RA (1 vs. > 1).  The sample size will provide > 90% 
power to demonstrate similarity on the primary PK endpoints based on an assumption of between-subject variability (as measured by coefficient of variation) of 40%, true 
geometric mean ratio (GMR) of 1 among ABP 798, rituximab (US), or rituximab (EU), a 
margin of (0.8, 1.25) and 15% dropout by week 24.  The PK similarity will be tested between ABP 798 versus rituximab (US) and ABP 798 versus rituximab (EU), each with a significance level of 0.05.  The similarity  between rituximab (US) and rituximab (EU) 
will be evaluated as well. 
12.3 Statistical Analysis Plan 
A SAP will be written and finalized prior to any lock of the study database.  The SAP will provide a detailed description of the statistical methods and expand on the details provided in the protocol.  Additional analyses may be added.  Table, listing, and figure shells will also be included. 
12.4 Randomization 
Randomization will be performed by an IX RS.  The randomization schedule will be 
prepared by a statistician not involved in t he conduct of the study.  Randomization will be 
stratified by geographic region, seropositivity (RF-positive and/or CCP-positive vs. RF-negative and CCP-negative), and number of prior biologic  therapies used for RA (1 vs. 
> 1).   
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 57 of 77 
Confidential   12.5 Analysis Populations 
The analysis for the PK endpoints will be based on the PK Analysis Set.  Sensitivity 
analysis for the PK endpoints will be based on the per-protocol PK Analysis Set.  The primary analysis for the PD endpoint and efficacy endpoints will be performed using the 
Full Analysis Set (FAS).  The Per-protocol Analysis Set will be used for sensitivity 
analyses of the key efficacy endpoints.  The analysis of safety endpoints will be based on the Safety Analysis Set. 
12.5.1 Full Analysis Set  
The FAS includes all subjects randomized in the study.  It will be analyzed according to 
randomized treatment group (regardless of actual treatment received).  
12.5.2 Per-protocol Set 
The Per-protocol Analysis Set includes all subjects randomized in the study who have 
completed the week 24 disease assessment and did not experience a protocol deviation that affects their evaluation of the secondary objectives of the study to assess clinical efficacy.  It will be analyzed according to actual treatment received.  The protocol 
deviations that affect evaluation of efficacy endpoints will be determined based on a 
blinded data review prior to database lock. 
12.5.3 Safety Analysis Set  
The Safety Analysis Set includes all random ized subjects who received at least 1 
infusion of investigational product.  It will be analyzed according to actual treatment received.  
12.5.4 Pharmacokinetic Analysis Set  
The PK Analysis Set includes all randomized subjects who received the full 
protocol-specified dose on Day 1  and had an evaluable serum concentration-time 
profile.  It will be analyzed according to actual treatment received.  
12.5.5 Per-protocol Pharmacokinetic Analysis Set  
The Per-protocol PK Analysis Set consists of a subset of subjects in the PK Analysis Set 
who do not experience a protocol deviation that affects their evaluation.  It will be analyzed according to actual treatment received.  The protocol deviations that affect evaluation of PK endpoints will be determined based on a blinded data review prior to database lock. 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 58 of 77 
Confidential   12.6 Statistical Methods 
The final analysis will be performed after all subjects have completed or have had 
the opportunity to complete the week 48/EOS assessment. Secondary analyses of 
long-term effects and safety will be performed after all subjects have had the opportunity 
to complete the week 48/EOS assessment. 
All categorical variables will be summarized using the number and percent of subjects 
falling into each category and all continuous variables will be summarized using mean, standard error or standard deviation, median, minimum, maximum, and number of 
subjects with observations.  Safety endpoints will be summarized descriptively.  
Subgroup analyses (by age, race, sex, and stratification factors as appropriate) will be presented if deemed necessary.  
The PK similarity for each primary PK endpoint will be tested between ABP 798 versus 
rituximab (US) and ABP 798 versus rituximab (EU), each with a significance level of 
0.05.   
12.6.1 Missing Data 
Imputation rules will be presented in the SAP before unblinding of the study for the final 
analysis.   
12.6.2 Demographic and Baseline Data 
The following demographic and baseline characteristics will be summarized:  age (in years, at time of signing informed consent), race, gender, ethnicity, height, and weight.  
Disease history and baseline disease characteristics will also be summarized. 
12.6.3 Subject Disposition 
The following information will be summarized for subject disposition and accountability: 
ï‚· number of subjects randomized will be tabulated by country, center, and 
stratification factor  
ï‚· subject disposition (including number of subjects who were screened, 
randomized, treated with ABP 798/rituximab [US]/rituximab [EU], completed 
treatment, discontinued treatment with reason for discontinuation, completed study, and discontinued study with reason for discontinuation) 
ï‚· summaries of analysis populations with reason for exclusion 
ï‚· important protocol deviations 
ï‚· number and percent of subjects on study at each visit  
ï‚· randomization list of subjects and their actual versus randomized treatment 
group 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 59 of 77 
Confidential   12.6.4 Pharmacokinetics 
The PK similarity will be demonstrated by compar ing the 90% confidence interval (CI) for 
the GMR of test (ABP 798)-to-reference (US-licensed rituximab or EU-authorized 
rituximab) and rituximab [US] to rituximab [EU]  for AUC inf and for  Cmax following the 
second infusion of the first dose with the bounds of 0.8 to 1.25, where ï¡=0.05.  PK 
parameters will be calculated using non-compartmental methods.  Point estimates and 
CIs for the GMR will be estimated from an analysis of covariance model using the PK Analysis Set. 
Other PK endpoints, AUC
0-14 day  after first infusion, AUC 0-12 wk  after the first and second 
infusions of the first dose and C max after the first infusion of the first dose, will be 
analyzed using the same methods as stated above.   Additional PK parameters including 
the time of C max (tmax), terminal elimination half-life (t 1/2), and the terminal elimination rate 
constant (Î» z) will be summarized descriptively. 
12.6.5 Pharmacodynamics 
The PD similarity will be evaluated descriptively  by calculating the 90% CI of complete 
CD19+ cell depletion rate difference between test-to-reference.  The 95% CI will also be 
provided.  The point estimate and CIs for rate difference will be estimated using a generalized linear model (specifically, a log-binomial regression model) with relevant baseline values and stratification factors as covariates using the FAS. 
12.6.6 Efficacy 
Clinical equivalence will be evaluated for DAS28-CRP at week 24 using the FAS 
consisting of all randomized subjects.  If PK similarity is established between 
rituximab (US) and rituximab (EU), the 2 arms will be combined into a single 
reference arm for the primary assessment of clinical equivalence between ABP 798 and rituximab.  The results for ABP 798 vs. rituximab (EU) and ABP 798 vs. 
rituximab (US) will be provided for descriptive purposes. If PK similarity is not 
established, the ABP 798 arm will be compared to each of the individual rituximab arms separately to  stablish clinical equivalence of ABP 798 to the individual reference arms. The 95% CI for both the difference between ABP 798 and US-licensed rituximab or EU-authorized rituximab in DAS28-CRP change from baseline will also be 
provided. 
With the planned sample size, there is 94%  probability that the 90% CI of the 
difference between the ABP 798 arm and the pooled rituximab (rituximab [EU] and 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 60 of 77 
Confidential   rituximab [US]) arm and 83% probability that the 90% CI of the difference between test 
(ABP 798) and reference (US-licensed rituximab or EU-authorized rituximab) in 
DAS28-CRP change from baseline at week 24 will fall into the equivalence margin of Â± 
0.6 (EULAR response criteria), assuming a standard deviation of 1.4 ( Volkmann et al, 
2010).  DAS28-CRP at other timepoints and ACR 20, 50 and 70 will be summarized 
descriptively.   
In addition, 90% and 95% CI for the risk ratio (RR) and risk difference (RD) of ACR20, 
ACR50  and ACR70 at week 24 between ABP 798 and rituximab (pooled US- licensed  
and EU-authorized rituximab , US-licensed rituximab or EU-authorized rituximab) will 
also be provided and the outcome is descriptive.  The CIs for the difference of DAS28-
CRP change from baseline between the ABP 798 and rituximab arms will be est imated 
using repeated-measures analysis.  Data from all assessed time points through week 24 visit will be included in the analysis.  Besides stratification variables, visit (week), 
treatment, and treatment-by-visit interaction will be included in the model, with visit as a categorical variable.  The CIs for RR and RD of ACR20 /50/70 between ABP 798 and 
rituximab arms will be estimated based on a repeated measures analysis where data 
from all assessed time points through week 24 visit are included.  Besides stratification 
variables, visit week (as a categorical variable), treatment, and treatment-by-visit interaction will be included in the generalized estimating equation (GEE) model.   
Other endpoints, RR and RD of ACR 20/ 50/70 at weeks 8, 12, 40, and 48, and RR and 
RD of ACR50 and ACR70 at weeks 8, 12, 40, and 48 will be summarized descriptively 
by treatment.  In addition, the difference of DAS28-CRP change from baseline between 
the ABP 798 and rituximab arms will be summarized descriptively by treatment at weeks 8, 12, 40, and 48. 
12.6.7 Safety 
All safety analyses will be performed using the Safety Analysis Set based on subjectâ€™s 
actual treatment received.  Safety analysis will include analyses of AEs, clinical 
laboratory tests, vital signs, ECGs, and antidrug antibodies.  In general, summaries will be provided separately for day 1 up to the 1
st infusion of the 2nd dose of investigational 
product by actual treatment groups, for the entire study by treatment groups defined by 
first dose, and for the day of the 1st infusion of the 2nd dose of investigational product up 
to the week 48/EOS visit with subjects grouped as receiving ABP 798 for both 1st and 2nd 
doses, receiving rituximab (US) for the 1st dose and ABP 798 for the 2nd dose, and 
receiving rituximab (EU) for both 1st and 2nd doses, unless otherwise specified.  
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 61 of 77 
Confidential   12.6.7.1 Investigational  Product Administration 
For the investigational product (ABP 798, rituximab [US], or rituximab [EU]), summary 
statistics will be provided for the total number of doses.   
12.6.7.2 Adverse Events 
Safety analyses will focus on treatment-emergent AEs.  Treatment-emergent events are 
those that begin or increase in severity or frequency at or after the time of first treatment 
up to the week 48/EOS visit (or within 28 days following the last dose of study treatment 
if subject discontinues study early).  All treatment-emergent AEs will be summarized by 
treatment arm and according to the MedDRA system organ class (SOC) and preferred 
term.  Summaries will be provided for the incidence of all treatment-emergent AEs and 
by severity and relatedness to investigational product.  Additional summaries will be presented for SAEs. 
All AE data will be listed by subject, and a separate listing will include all SAEs, including 
any deaths on study. 
AEs of special interest ( Section 11.3 ) will be summarized separately.   
The exposure adjusted subject incidence rates of adverse events throughout the study 
may be tabulated for selected categories of adverse events
. 
12.6.7.3 Immunogenicity 
The number and percentage of subjects developing antidrug antibodies and those 
developing neutralizing antibodies will be tabulated separately for day 1 to the 1st 
infusion of the 2nd dose of investigational product by actual treatment groups, and for 
day 1 of first infusion of second dose to 4 weeks after the 2nd infusion of the 2nd dose and 
for the entire study by treatment groups defined by first dose.  
12.6.7.4 Concomitant Medications and Therapies 
Concomitant medications will be coded by WHODRUG and will be summarized by treatment group with number and percentage of subjects receiving each category of 
medication. 
12.6.7.5 Clinical Laboratory Test 
Clinical laboratory test results and change from baseline will be summarized by time 
point .  In addition, shift tables, from baseline to the worst on-study laboratory toxicity 
based on CTCAE v4 grading, will be presented. 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 62 of 77 
Confidential   12.6.7.6 Vital Signs and Physical Examinations 
Vital sign data (observed and change from baseline) will be summarized using 
descriptive statistics by time point and treatment.   
Abnormal findings from physical examinations will be listed by subject and assessed for 
clinical significance, which will be included in the AE listings and summaries. 
12.6.8 Interim Analysis 
No formal interim analysis is planned for this study. 
12.6.9 Data Monitoring Committee 
A DMC external to Amgen and PRA will be formed with members consisting of 
individuals chosen for their expertise in r heumatology.  Members of the DMC will include 
at a minimum, physicians external to Amgen and PRA, and appropriate statistical representation external to Amgen and PRA.  The primary role of this independent DMC will be to monitor safety data.  
The DMC will review unblinded safety data at regular intervals, as outlined in the DMC 
charter (approximately twice yearly; the st art date will depend on subject accrual rates). 
In addition, the DMC will conduct an initial safety analysis after the first 18 subjects have received at least 1 dose of investigational  product (ie, infusions on days 1 and 15) of 
either ABP 798, rituximab (US) or rituximab (EU).   
The DMC will communicate major safety concerns and recommendations regarding 
study modification or termination to Amgen management at any time during the conduct 
of the study.  
Records of all meetings will be archived.  Selected Amgen, or its designee, staff may 
serve as liaisons to the external DMC, but will not be voting members and will not be unblinded to the results.  Details regarding the DMC will be provided in the DMC charter. 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 63 of 77 
Confidential   13 MONITORING PROCEDURES (QUALITY ASSURANCE) 
Amgen has ethical, legal, and scientific obligations to conduct this study in accordance 
with established research principles and ICH GCP guidelines.  As such, in order to fulfill these obligations and to maintain current of study progress, Amgen monitors, or 
Amgenâ€™s designees, will visit the investigative sites during study conduct, in addition to 
maintaining telephone and written communication.  On-site visits, telephone calls, and regular inspection of the eCRFs will be conducted in order to assess subject enrollment, compliance with protocol procedures, completeness and accuracy of data entered on the 
eCRFs, verification of eCRF data against original source documents, and occurrence of 
AEs.  The Investigator must provide the monitor with full access to all source and study documents. 
13.1 Routine Monitoring 
Amgen, or its designee, assigned monitors will conduct regular site visits to the investigational facilities for the purpose of monitoring various aspects of the study.  The 
Investigator must agree to Amgen, or its designee, authorized personnel having direct 
access to the clinical (or associated) files and clinical study supplies (dispensing and storage areas) for all study subjects cons idered for study entry for the purpose of 
verifying entries made in the eCRF, and assist with their activities, if requested.  
Adequate time and space for monitoring visits should be made available by the 
Investigator. 
The site must complete the eCRFs in a timely manner and on an ongoing basis to allow 
regular review by the study monitor. 
Whenever a subject name is revealed on a document that is to be collected for the 
Sponsor, the name must be blacked out permanently by the site personnel, leaving the 
initials visible, and must be annotated with the subject number as identification. 
13.2 Inspections and Auditing Procedures 
Amgen, or its designee, may conduct audits at the investigative sites, including, but not limited to, drug supply, presence of required documents, the informed consent process, 
and comparison of eCRFs with source documents.  All medical records (progress notes) 
must be available for audit.  The Investigator agrees to participate with audits conducted at a convenient time in a reasonable manner. 
Government regulatory authorities may also inspect the Investigator during or after the 
study.  The Investigator or designee should contact Amgen, or its designee, immediately 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 64 of 77 
Confidential   if this occurs.  He/she must cooperate fully with regulatory authorities or other audits 
conducted at a convenient time in a reasonable manner. 
The purpose of an audit is to assess whether ethics, regulatory and quality requirements 
are fulfilled. 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 65 of 77 
Confidential   14 STUDY MANAGEMENT AND MATERIALS 
14.1 Electronic Case Report Forms 
An eCRF will be used to store and transmit subject information.  The file structure and 
format for the eCRF will be provided by the Sponsor or their representative and should be handled in accordance with the instructions provided. 
The eCRF must be reviewed and electronically signed and dated by the Investigator. 
Access to the eCRF will be strictly password protected and limited to personnel directly 
participating in the study.  Data should be entered into the eCRF completely by examining personnel or the appropriate site staff.  The eCRF must be completed as 
soon as possible after any subject evaluation or communication.  If data are to be 
changed due to erroneous input or other reason, an electronic audit trail will track these changes.  The eCRFs and computers that store them must be accessible to study monitors and other regulatory auditors. 
14.2 Data Collection 
During each study visit, a physician participating in the study will maintain progress 
notes in the subjectâ€™s medical records to document all significant observations.  At a 
minimum, these notes will contain: 
ï‚· the date of the visit and the corresponding day or visit in the study schedule (eg, 
screening, day 1, week 2, etc). 
ï‚· general condition and status remarks by the subject, including any significant 
medical findings.  The severity, frequency, duration, and resolution of any 
reported AE, and the Investigator's assessment as to whether or not the reported AE is investigational product-related. 
ï‚· changes in concomitant medications or dosages. 
ï‚· a general reference to the procedures completed. 
ï‚· the signature or initials of all physicians making an entry in the medical record 
(progress notes). 
In addition, any contact with the subject via telephone or other means that provides 
significant clinical information will also be documented in the medical record (progress notes), as described above.  
Information from the medical records (progress notes) and other source documents will 
be promptly transcribed to the appropriate section of the eCRF. 
Changes to information in the medical record (progress notes), CRF, and other source 
documents will be initialed and dated on the day the change is made by the Investigator 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 66 of 77 
Confidential   or designee.  If the reason for the change is not apparent, a brief explanation for the 
change will be written adjacent to the change. 
14.3 Source Documents Maintenance 
Source documents contain the results of origin al observations and activities of a clinical 
investigation.  Source documents include, but are not limited to, medical records (progress notes), computer printouts, screening logs and recorded data from automated instruments.  
All source documents from this study will be maintained by the Investigator and made 
available for inspection by authorized persons.  The original signed informed consent for 
each subject shall be filed with records kept by the Investigator and a copy shall be given to the subject. 
14.4 Record Maintenance 
All data derived from the study will remain the property of Amgen Inc. 
Records must be retained in accordance with the current ICH Guidelines on GCP.  All 
essential study documents including records of subjects, source documents, eCRFs and 
investigational product inventory must be kept on file. 
Essential documents should be retained until at least 2 years after the last approval of a 
marketing application in an ICH region and until there are no pending or contemplated 
marketing applications in an ICH region, or until at least 2 years have elapsed since the 
formal discontinuation of clinical development of the investigational products.  However, essential documents may be retained for a longer period if required by the applicable regulatory requirements or by agreement with the Sponsor.   
The Investigator shall take responsibility for maintaining adequate and accurate hard 
copy source documents of all observations and data generated during this study.  Such 
documentation is subject to inspection by the Sponsor, its representatives, and regulatory authorities. 
If an Investigator moves, withdraws from an investigation, or retires, the responsibility for 
maintaining the records may be transferred to another person who will accept 
responsibility.  Notice of transfer must be made to and agreed by the Sponsor. 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 67 of 77 
Confidential   14.5 Confidentiality 
All information obtained during the conduct of the study with respect to the subjectâ€™s 
state of health will be regarded as confidential.  For disclosure of any such information, an agreement will be obtained in writing.  
The Investigator must ensure that each subjectâ€™s anonymity is maintained.  On eCRFs 
and other documents submitted to the Sponsor or the CRO, subjects must not be identified by name.  Instead, subjects will only be known by the unique subject number allocated to them in order to ensure confidentiality on all study documentation.  Subjects 
will retain this unique number throughout the study.  The Investigator will keep a 
separate log of these codes. 
In order to comply with government regulatory guidelines and to ensure subject safety, it 
may be necessary for the Sponsor and its representative, the CRO personnel, the local research review board, or the US FDA to review subjectsâ€™ medical records as they relate 
to this study.  Only the subjectâ€™s unique number on the eCRFs will identify him/her, but 
their full names may be made known to a drug regulatory authority or other authorized government or health care officials, if necessary, and to personnel designated by the 
Sponsor. 
Documents that are not for submission to t he Sponsor or the CRO (eg, consent forms) 
will be maintained by the Investigator in strict confidence, except to the extent necessary 
to allow monitoring by the Sponsor and the CRO, and auditing by regulatory authorities.  No documents identifying subjects by name will leave the investigative site and subject identity will remain confidential in all publications related to the study. 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 68 of 77 
Confidential   15 ADMINISTRATION PROCEDURES 
15.1 Regulatory Approval 
Amgen Inc., or their appointed agents, will be responsible for ensuring that appropriate 
regulatory authority approvals are obtained, according to local country requirements. 
No subject may enter the study until this approval has been obtained.  A copy of the 
approval (where one is provided as requested, according to local country requirements) 
will be provided to the Investigator and to the IRB(s)/IEC(s). 
15.2 Protocol Amendments 
In accordance with ICH Topic E 6 (R1) Guideline for GCP the Investigator should not implement any deviation from or changes of  the protocol without agreement by the 
Sponsor and documented approval from the IRB /IECs of a protocol amendment, except 
where necessary to eliminate an immediate hazard(s) to study subjects, or when the change(s) involves only logistical or administrative aspects of the study (eg, change in monitor[s], change of telephone number[s]).  
Any change to the protocol must be handled as a protocol amendment.  Any potential 
amendment must be approved by the Sponsor.  A written amendment must be 
submitted to the appropriate regulatory authorities and to the IRB/IECs assuming this responsibility.  The Investigator must await IRB/IEC approval of protocol amendments before implementing the changes, except where necessary to eliminate apparent 
immediate hazard to subjects.  In these cases, the IRB/IEC must be notified within 
5 days of the change. 
All amendments to the protocol must be approved in writing by both the appropriate 
regulatory authorities and the IRB/IEC, exc ept for administrative amendments, which 
require notification but not written approval.  Once approved, the protocol amendment 
will be distributed to all recipients of the original protocol, with instructions to append the 
amendment to the protocol. 
If, in the judgment of the local IRB/IEC, the Investigator and/or Sponsor, the protocol 
amendment alters the study design or procedures and/or increases the potential risk to 
the subject, the currently approved written ICF will require modification.  The modified 
ICF must also be reviewed and approved by the Sponsor, appropriate regulatory authorities, and the IRB/IEC.  In such cases, repeat informed consent must be obtained from subjects enrolled in the study before participation continues. 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 69 of 77 
Confidential   15.3 Protocol Adherence and Deviations 
The protocol must be read thoroughly, and the instructions must be followed.  However, 
exceptions will be made in emergency sit uations when the protection, safety, and 
well-being of the subject requires immediate intervention based on the judgment of the 
Investigator or (a) responsible, appropriately trained, and credentialed professional(s) 
designated by the Investigator as a sub-investigator.  
In the event of a significant protocol deviation due to an emergency, accident, or error, 
the Investigator or designee must contact the Medical Monitor at the earliest possible 
time by telephone.  This allows for an early joint decision to be made as to whether or 
not the subject should continue in the study.  The Investigator, Sponsor, and Medical Monitor will document this decision. 
15.4 Publication Policy 
Authorship of any publications resulting from this study will be determined on the basis of the Uniform Requirement for Manuscripts Submitted to Biomedical Journals 
(International Committee of Medical Journal Editors), which states: 
ï‚· Authorship credit is to be based on (1) substantial contributions to conception 
and design, acquisition of data, or analysis and interpretation of data; (2) drafting 
the article or revising it critically for important intellectual content; (3) final 
approval of the version to be published; 4) agreement to be accountable for all 
aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.  Authors are to meet conditions 1, 2, 3, and 4. 
ï‚· When a large, multicenter group has conducted the work, the group is to identify 
the individuals who accept direct responsibility for the manuscript.  These individuals are to fully meet the criteria for authorship defined above. 
ï‚· Acquisition of funding, collection of data, or general supervision of the research 
group, alone, does not justify authorship. 
ï‚· All persons designated as authors are to qualify for authorship, and all those 
who qualify are to be listed. 
ï‚· Each author is to have participated sufficiently in the work to take public 
responsibility for appropriate portions of the content. 
All publications (eg, manuscripts, abstracts, oral/slide presentations, book chapters) 
based on this study must be submitted to Amgen for review.  The Clinical Trial Agreement between the institution, Investigator, and Amgen will detail the procedures for, and timing of, Amgenâ€™s review of publications. 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 70 of 77 
Confidential   15.5 Clinical Study Report 
A final clinical study report will be prepared according to the ICH guideline on Structure 
and Contents of Clinical Study Reports.  A final clinical study report will be prepared regardless of whether the study is completed or prematurely terminated.    
15.6 Contractual and Financial Details 
The Investigator (and/or, as appropriate, the hospital administrative representative) and 
Amgen, or its designee, will sign a clinical study agreement prior to the start of the study, outlining overall Amgen, or its designee, and Investigator responsibilities in relation to the study.  Financial Disclosure Statements will be completed only as required by local 
regulations. 
15.7 Compensation 
Any arrangements for compensation to subjects for injury or illness that arises in the 
study are described in the Compensation for Injury section of the Informed Consent that is available as a separate document. 
15.8 Discontinuati on of the Study 
This study may be terminated by Amgen at any time.  In terminating the study, Amgen, 
the CRO (PRA) and the Investigator will ensure that adequate consideration is given to protection of the subjectsâ€™ interests.  Amgen will not provide ABP 798 or rituximab after termination of the trial or upon discontinuation of the study for the subject. 
15.9 Study Center File Management 
The Investigator is responsible for assuring that the Study Center File is maintained.  The Study Center File will contain, but not be limited to, the information listed below: 
1. Investigatorâ€™s Brochure 
2. Current, signed version of the protocol and any previous versions of the protocol 
3. Protocol amendments (if applicable) 4. Operations Manual (if applicable) 5. Current ICF (blank) and any previous versions of the ICF 6. Curricula Vitae of Investigator(s) and sub-investigator(s) and photocopy of their 
respective license(s) where required by law; Original US FDA Form 1572 (for all studies conducted under US Investigational New Drug [IND] regulations), signed by all Principal Investigators.  The names of any sub-investigators must appear on this form.  Investigators must also complete all regulatory documentation as required the ICH GCP and by local or national regulations 
7. Documentation of IRB/IEC approval of the protocol, the ICF, any protocol 
amendments, and any ICF revisions 
8. All correspondence between the Investigator, IRB/IEC, and the Sponsor/CRO 
relating to study conduct 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 71 of 77 
Confidential   9. Lab certification(s) 
10. Monitoring log 
11. Investigational product invoices 
12. Signature list of all staff completing eCRFs 13. Signature list of all staff completing drug accountability summaries 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 72 of 77 
Confidential   16 REFERENCE LIST 
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 
rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. 
Arthritis Rheum. 2010;62: 2569â€“81. 
Biogen Idec, Inc. and Genentech, Inc.  RituxanÂ® (rituximab) Injection for Intravenous 
Infusion.  Package Insert.  September 2013. 
BlÃ¼ml S, McKeever K, Ettinger R, et al.  B-cell targeted therapeutics in clinical 
development.  Arth Res Ther.  2013;15(Suppl 1):S4-S25. 
CHMP/437/04 Rev 1(draft).  Guideline on similar biological medicinal products.   Choy EH, Panayi GS.  Cyto kine pathways and joint inflammation in rheumatoid 
arthritis.  N Engl J Med. 2001;344(12):907-16. Cohen SB, Emery P, Greenwald MW, et al.  Rituximab for rheumatoid arthritis 
refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, 
double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.  Arthritis Rheum. 2006 Sep;54(9):2793-806. 
EMEA/CHMP/BWP/247713/2012 (Rev1)(draft).  Guideline on similar biological 
medicinal products containing biotechnology-derived proteins as active substance:  
quality issues.  
EMEA/CHMP/BMWP/42832/2005 Rev.1.(draft).  Guideline on similar biological 
medicinal products containing Biotechnology-derived proteins as active substance:  Non-clinical and clinical issues.   
Hochberg MC, Rowland WC, Dwosh I, et aI. The American College of Rheumatology 
1991 Revised Criteria for the Classification of Global Functional Status in Rheumatoid Arthritis. Arthritis & Rheumatism. 1992;35(5):498-502. 
McInnes IB, Schett G.  Cytokines in the pathogenesis of rheumatoid arthritis.  Nat 
Rev Immunol. 2007;7(6):429-42.  
Roche Pharma AG.  MabTheraÂ® (rituximab) Injection for Intravenous Infusion.  
Package Insert.  May 2016. 
Tuscano JM, Sands J.  B cell reductive therapy with rituximab in the treatment of 
rheumatoid arthritis.  Biologics:  Target & Therapy.  2009;3:225-32. 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 73 of 77 
Confidential   US FDA.  Guidance for Industry:  Scientific considerations in demonstrating 
biosimilarity to a reference product.  February 2012a, US FDA (draft). 
US FDA.  Guidance for Industry:  Quality considerations in demonstrating 
biosimilarity to a reference protein product.  February 2012b, US FDA (draft). 
van Gestel AM, Haagsma CJ, van Riel PL.  Validation of rheumatoid arthritis 
improvement criteria that include simplified joint counts.  Arthritis Rheum. 1998 Oct;41(10):1845-50. 
Volkmann ER, Agrawal H, Maranian P, Furst DE.  Rituximab for rheumatoid arthritis: 
A meta-analysis and systematic review.  Clin Med Insights: Therapeutics 2010:2 749-760. 
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 74 of 77 
Confidential   17 APPENDICES 
17.1 Appendix 1: Elements of Informed Consent 
ELEMENTS OF INFORMED CONSENT 
Both the informed consent discussion and the written ICF and any other written 
information to be provided to subjects should include explanations of the following: 
 
ï‚· That the study involves research. 
ï‚· The purpose of the study. 
ï‚· The study treatment(s) and the probability for random assignment to each 
treatment. 
ï‚· The study procedures to be followed including all invasive procedures. 
ï‚· The subjectâ€™s responsibilities. 
ï‚· Those aspects of the study that are experimental. 
ï‚· The reasonably foreseeable risks or inconveniences to the subject and, when 
applicable, to an embryo, fetus, or nursing infant. 
ï‚· The reasonably expected benefits.  When there is no intended clinical benefit to 
the subject, the subject should be made aware of this. 
ï‚· The alternative procedure(s) or course(s) of treatment that may be available to 
the subject, and their important potential benefits and risks. 
ï‚· The compensation and/or treatment available to the subject in the event of 
study-related injury. 
ï‚· The anticipated prorated payment, if any, to the subject for participating in the 
study. 
ï‚· The anticipated expenses, if any, to the subject for participating in the study. 
ï‚· That the subjectâ€™s participation in the study is voluntary and that the subject may 
refuse to participate or withdraw from the study, at any time, without penalty or 
loss of benefits to which the subject is otherwise entitled. 
ï‚· That the monitor(s), the auditor(s), the IRB/IEC, and the regulatory authority(ies) 
will be granted direct access to the subjectâ€™s original medical records for 
verification of clinical study procedures and/or data, without violating the 
confidentiality of the subject, to the extent permitted by the applicable laws and regulations and that, by signing a written ICF, the subject or the subjectâ€™s legally acceptable representative is authorizing such access. 
ï‚· That records identifying the subject will be kept confidential and, to the extent 
permitted by the applicable laws and/or regulations, will not be made publicly available.  If the results of the study are published, the subjectâ€™s identity will 
remain confidential. 
ï‚· That the subject or the subjectâ€™s legally acceptable representative will be 
informed in a timely manner if information becomes available that may be 
relevant to the subjectâ€™s willingness to continue participation in the study. 
ï‚· The person(s) to contact for further information regarding the study and the 
rights of study subjects, and whom to contact in the event of study-related injury. 
ï‚· The foreseeable circumstances and/or reasons under which the subjectâ€™s 
participation in the study may be terminated. 
ï‚· The expected duration of the subjectâ€™s participation in the study. 
ï‚· The approximate number of subjects involved in the study. 
  
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 75 of 77 
Confidential   17.2 Appendix 2: American College of Rheumatology Revised Criteria for 
the Classification of Functi onal Capacity in RA 
American College of Rheumatology revised criter ia for classification of functional status 
in rheumatoid arthritis a 
Class I Completely able to perform usual activities of daily living (self-care, 
vocational, and avocational) 
Class II Able to perform usual self-care and vocational activities, but limited in 
avocational activities 
Class III Able to perform usual self-care activities, but limited in vocational and 
avocational activities 
Class IV Limited in ability to perform usual self-care, vocational, and avocational 
activities 
a Usual self-care activities include dressing, feeding, bathing, grooming, and toileting.  
Avocational (recreational and/or leisure) and vocational (work, school, homemaking) 
activities are patient-desired and age- and sex-specific. 
Hochberg MC, Rowland WC, Dwosh I, et aI. The American College of Rheumatology 
1991 Revised Criteria for the Classification of Global Functional Status in Rheumatoid Arthritis. Arthritis 
& Rheumatism. 1992;35(5):498-502. 
  
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 76 of 77 
Confidential   17.3 Appendix 3: DAS28 and ACR Core Set Measurements 
DAS28 Core Set Measurements: 
ï‚· tender joint count 
ï‚· swollen joint count 
ï‚· Subject's Global Health Assessment 
ï‚· CRP  
ACR Core Set Measurements: 
ï‚· tender joint count 
ï‚· swollen joint count 
ï‚· Subject's Global Health Assessment 
ï‚· Investigator's Global Health Assessment 
ï‚· Subject's assessment of pain 
ï‚· Health Assessment Questionnaire â€“ Disability Index (HAQ-DI) 
ï‚· CRP  
Joints to be Assessed for Swelling and Tenderness 
The joints to be assessed for tenderness (68 joints) and swelling (66 joints) consist of 
the following: 
ï‚· temporomandibular joint 
ï‚· sternoclavicular joint 
ï‚· acromioclavicular joint 
ï‚· shoulders* 
ï‚· elbows* 
ï‚· wrists* 
ï‚· interphalangeal on digit 1* 
ï‚· distal interphalangeal joints on digits 2 - 5 
ï‚· proximal interphalangeal joints on digits 2 - 5* 
ï‚· metacarpophalangeal joints on digits 1 - 5* 
ï‚· hips (tenderness only) 
ï‚· knees* 
ï‚· ankles 
ï‚· metatarsals 
ï‚· interphalangeal joints on toes 1 - 5 
ï‚· metatarsophalangeal joints on toes 1 - 5 
Joints assessed for swelling are the same, with the exception of the hips, which are excluded. 
* The 28 joints used to calculate the DAS28.
Product: ABP 798 
Clinical Study Protocol: 20130108 Date: 20 March 2018 Page 77 of 77 
Confidential    
17.4 Appendix 4: Subjective Assessment Scales 
Subject's Assessment of Disease Related Pain: 
The subject's assessment of their current level of pain on a 100-mm VAS.  The left-hand 
extreme of the line should be described as "no pain at all" and the right-hand extreme as 
"worst pain imaginable." 
Subject's Global Health Assessment: 
The subject's overall assessment of their disease activity in the past week on a 100-mm 
VAS. The left-hand extreme of the scale will be described as "no RA activity at all" (symptom-free and no arthritis symptoms) and the right-hand extreme as "worst RA 
activity imaginable" (maximum arthritis disease activity). 
Investigator's Global Health Assessment: 
The Investigator's assessment of the subject's current disease activity on a 100-mm 
VAS. The left-hand extreme of the scale will be described as "no activity at all" (symptom-free and no arthritis symptoms) and the right-hand extreme as "worst activity 
imaginable" (maximum arthri tis disease activity). 
Health Assessment Questionnaire-Disability Index 
The HAQ-DI is a questionnaire on which subjects are asked to rate their level of difficulty 
on daily activities (dressing and grooming, arising, eating, and walking) and personal 
abilities (hygiene, reach, grip, and activity), as well as their use of aids, devices, or help 
from another person for these activities and disabilities. 
 
Product: ABP  798 
Clinical Study Protocol: 2013010 8 
Date:  20 March 2018  Page 1 of 7 
 
Confidential   
 
A RANDOMIZED, DOUBLE -BLIND STUDY TO COMP ARE 
PHARMACOKINETICS AND  PHARMACODYNAMICS, E FFICACY AND 
SAFETY OF ABP 798 WI TH RITUXIMAB IN SUBJ ECTS WITH MODERATE 
TO SEVERE RHEUMATOID  ARTHRITIS  
 
SUMMARY OF CHANGES  
 
Test Drug:  ABP 798 
Protocol Number:  20130108  EudraCT number:  2013 -005543 -90 
Study Phase:   1/3   
Date and Version:  20 March 2018 , 4.0  
Sponsor : 
 
Amgen Inc.  
One Amgen Center Drive  
Thousand Oaks, CA 91320  US 
 Clinical Research Organization (CRO):  
 
PRA Health Sciences  
4130 ParkLake Avenue  
Raleigh, NC 27612 US  
  
 
  
This study will be conducted in compliance with the protocol, Good Clinical Practice 
(GCP) as set forth in the International Conference on Harmonisation (ICH) guidelines on 
GCP (ICH E6), and applicable local regulatory requirements.  
 
 
CONFIDENTIAL  This document is a confidential communicati on of  Amgen, Inc . Acceptan ce of this document constitutes 
agreement by the recipient that no unpublished information contained herein shall be published or 
disclosed without prior written approval, except that this document may be disclosed to the appropriate  
Institutional Review Board(s)/Independent Ethics Committee(s)  under the condition that they keep it 
confidential.  
Product: ABP  798 
Clinical Study Protocol: 2013010 8 
Date:  20 March 2018  Page 2 of 7 
 
Confidential   
 
Rationale:  
This amendment is issued to make the following changes:  
 
Update the Table of Contents to reflect the correct title of Appendix 3 . 
Delete the primary analysis as the revised regulatory filing strategy nullifies the  
 need for it. 
Clarify  the ACR improvement description.  
Added a secondary objective to demonstrate the PK similarity  of rituximab (US) a 
rituximab (EU).  
Update the sample size estimation and statistical methods language  to clarify the 
efficacy analysis.  
Clarify the efficacy measur ements, procedures , and remove redundancies  as needed . 
Specify the statistical approach for the efficacy evaluation.  
Update to clarify the dosing requirement for inclusion in the PK analysis population  
   
  
Product: ABP  798 
Clinical Study Protocol: 2013010 8 
Date:  20 March 2018  Page 3 of 7 
 
Confidential   
 
Summary of Changes  
Any changes in the synopsis that also appear in the body of t he protocol will appear only 
once in this summary of changes document, under the section number.   Additions are in 
bold and deletions are in strikethrough.  
Section 2, Synopsis, Objectives  
Section 7.2, Secondary Objectives  
Add:  
â€¢ to demonstrate PK similarity  between rituximab (US) and rituximab (EU) as 
assessed by AUC inf and by C max after second infusion of the first dose  
Section 2, Synopsis, Study Design and Methodology  
Section 8.1, Overall Study Design and Plan  
Remove:  
The primary analysis will be conducted  when all subjects have completed or have had 
the opportunity to complete the week 30 assessments . 
Section 2, Synopsis, Study Evaluations, Secondary Criteria  
Add: 
â€¢ ACR20,  ACR50 and ACR70    
 
Section 2, Synopsis, Statistical Methods  
Replace:  
The PK similarity will be demonstrated by comparing the 90% confidence interval (CI) for 
the GMR of test (ABP 798) -to-reference (rituximab [US] or rituximab [EU]) for AUC inf and 
Cmax following the second infusion of the first dose with the bounds of 0.8 to  1.25, where 
Î±=0.05 . 
Clinical equivalence will be evaluated for DAS28 -CRP at week  24 using the Full Analysis 
Set consisting of all randomized subjects .  With the planned sample size, there is 83% 
probability that the 9 0% CI of the difference between test ( ABP 798) and reference 
(rituximab [US] or rituximab  [EU]) in DAS28 -CRP change from baseline will fall into the 
equivalence margin of Â± 0.6 (EULAR response criteria),  assuming a standard deviation 
of 1.4 (Volkmann, 2012) . The 95% CI for both the difference between ABP 798 and US -
licensed rituximab or EU authorized rituximab in DAS28 CRP change from baseline will 
also be provided . 
With:  
The PK similarity will be demonstrated by comparing the 90% confidence interval (CI) for 
the GMR of test (ABP 798) -to-refere nce (rituximab [US] or rituximab [EU]) and 
rituximab [US] to rituximab  [EU] for AUC inf and for Cmax following the second infusion 
of the first dose with the bounds of 0.8 to 1.25,  where Î±=0.05 .   
Clinical equivalence will be evaluated for DAS28 -CRP at week  24 using the Full Analysis 
Set consisting of all randomized subjects . If PK similarity is established  between 
Product: ABP  798 
Clinical Study Protocol: 2013010 8 
Date:  20 March 2018  Page 4 of 7 
 
Confidential   
 
rituximab (US) and rituximab (EU) , the 2 arms  will be combined into a single 
reference arm for the primary assessment of clinical equivalence  between ABP 
798 and rituximab.  The results for ABP 798 vs. rituximab (EU) and ABP 798 vs. 
rituximab (US) will be provided for descriptive purposes. If PK similarity is not 
established, the ABP 798 arm will be compared to each of the individual rituximab 
arms separately to establish clinical equivalence of ABP 798 to the individual 
reference arms.   
With the planned sample size, there is 94% probability that the 90% CI of the 
difference between the ABP 798 arm and the pooled rituximab (rituximab[EU] and 
rituximab[US]) arm and  83% probability that the 90% CI of the difference between  test 
(ABP 798) and reference (US -licensed rituximab or EU-authorized rituximab)  in 
DAS28 -CRP change from baseline  at week 24  will fall into the equivalence margin of Â± 
0.6 (EULA R response criteria) , assuming a standard deviation of 1.4 ( Volkmann et al, 
2010 ). DAS28 -CRP at other timepoints and ACR20, 50 and 70 will be summarized 
descriptively.   
Section 8.6.1.2 .1, Efficacy Criteria  
Replace:   
ACR 20 
To achieve ACR20 response, at least 20% improvement compared to baseline is 
required for both swollen and tender joint counts (66/68 joint counts; Section  Error! 
Reference source not found. ), as well as for 3 out of the following 5  additional 
parameters:  
 
With:  
 
ACR  
 
Improvement compared to baseline is required for both swollen and tender joint counts 
(66/68 joint counts; Section  Error! Reference source not found. ), as well as for 3 out 
of the following 5  additional parameters:  
 
Section 12.5.4, Pharmacokinetic Analysis Set  
Replace:  
 
The PK Analysis Set includes all randomized subjects who received at least 1 infusion of 
investigational product and had an evaluable serum concentration -time profile.  It will be 
analyzed according to actual treatment received.  
  
Product: ABP  798 
Clinical Study Protocol: 2013010 8 
Date:  20 March 2018  Page 5 of 7 
 
Confidential   
 
With:  
The PK A nalysis Set includes all randomized subjects who received the full 
protocol -specified dose on Day 1  and had  an evaluable s erum concentration -time 
profile.  It will be analyzed according to  actual treatment received . 
 
 
Section 12.6, Statistical Methods  
Replace:  
 
The primary analysis will be performed after all subjects have complet ed or have had the 
opportunity to complete the week 30 assessments.  Secondary analyses of long -term 
effects and safety will be performed after all subjects have had the opportunity to 
complete the week 48/EOS assessment.  
With:  
The final analysis will be performed  after all subjects have completed or have had 
the opportunity to complete the week 48/EOS assessment.  Secondary analyses of 
long-term effects and safety will be performed after all subjects have had the opportunity 
to complete the week 48/EOS asse ssment.  
Section 12.6.1, Missing Data  
Replace:  
Imputation rules will be presented  in the SAP before unblinding of the study for the 
primary analysis.  
With:  
Imputation rules will be presented  in the SAP before unblinding of the study for the final 
analysis.  
Section 12.6.4, Pharmacokinetics   
Replac e:  
 
The PK similarity  will be demonstrated by comparing the 90% confidence interval (CI) for 
the GMR of test ( ABP 798)-to-reference ( US-licensed rituximab or EU-authorized 
rituximab ) for AUC inf and for AUC inf after first and second infusions and C max after second 
infusion of the first dose with the bounds of 0.8  to 1.25, where ï¡=0.05 .   
 
With:  
The PK similarity will be demonstrated by comparing the 90% confidence interval (CI) for 
the GMR of test (ABP 798) -to-reference (rituximab [US] or rituximab [EU]) and 
rituximab [US] to rituximab  [EU] for AUC inf and for C max following the second  
infusion of the first dose with the bounds of 0.8 to 1.25,  where Î±=0.05 . 
 
Section 12.6.6, Efficacy  
Replace:  
 
Clinical  equivalence will be evaluated for DAS28 -CRP at week 24 using the FAS 
consisting of all randomized subjects. With the planned sample size, there is 83% 
probability that the 90% CI of the difference between test (ABP 798) and reference (US  
licensed rituxima b or EU -authorized rituximab) in DAS28 -CRP change from baseline will 
Product: ABP  798 
Clinical Study Protocol: 2013010 8 
Date:  20 March 2018  Page 6 of 7 
 
Confidential   
 
fall into the equivalence margin of Â± 0.6 (EULAR response criteria), assuming a standard 
deviation of 1.4 (Volkmann et al, 2010). The 95% CI for both the difference between 
ABP 798 and US -licensed rituximab or EU -authorized rituximab in DAS28 -CRP change 
from baseline will also be provided.  In addition, 90% and 95% CI for the risk ratio (RR) 
and risk difference (RD) of ACR20 at week 24 between ABP 798 and US licensed  
rituximab or EU -author ized rituximab will also be provided,  and the outcome is 
descriptive.  The CIS for  the difference of DAS28 -CRP change from baseline between 
the ABP 798 and rituximab arms will be estimated using repeated -measures analysis. 
Data from all assessed time points through week 24 visit will be included in the analysis.  
Besides stratification variables, visit (week), treatment, and treatment -by-visit interaction 
will be included in the model, with visit as a categorical variable.   The CIs for RR and RD 
of ACR20 between ABP 798 and rituximab arms will be estimated based on a repeated 
measures an alysis where data from all assessed time points through week 24 visit are 
included.  Besides stratification variables, visit week (as a categorical variable), 
treatment, and treatment -by-visit interaction will be included in the generalized 
estimating equa tion (GEE) model.   Other endpoints, RR and RD of ACR20 at weeks 8, 
12, 40, and 48, and  RR and RD of ACR50 and ACR70 at weeks 8, 12, 24, 40, and 48 
will be summarized descriptively by treatment. In addition, the difference of DAS28 -CRP 
change from baseline between the ABP 798 and rituximab arms will be summarized 
descriptively by treatment at weeks 8, 12, 40, and 48.  
 
With:  
Clinical equivalence will be evaluated for DAS28 -CRP at week 24 using the FAS 
consisting of all randomized subjects.  If PK similarity i s established  between 
rituximab (US) and rituximab (EU) , the 2 arms  will be combined into a single 
reference arm for the primary assessment of clinical equivalence between ABP 
798 and rituximab.  The results for ABP 798 vs. rituximab (EU) and ABP 798 vs. 
rituximab (US) will be provided for descriptive purposes. If PK similarity is not 
established, the ABP 798 arm will be compared to each of the individual rituximab 
arms separately to  stablish clinical equivalence of ABP 798 to the individual 
reference arms . The 95% CI for both the difference between ABP 798 and US-licensed 
rituximab or EU-authorized rituximab  in DAS28 -CRP change from baseline will also be 
provided.  
 
With the planned sample size, there is  94% probability that the 90% CI of the 
difference between the ABP 798 arm and the pooled rituximab (rituximab [EU] and 
rituximab [US]) arm and  83% probability that the 90% CI of the difference between test 
(ABP 798) and reference (US -licensed rituximab or  EU authorized rituximab) in DAS28 
CRP change from baseline at week 24 will fall into the equivalence margin of Â± 0.6 
(EULAR response criteria), assuming a standard deviation of 1.4 (Volkmann et al, 2010).  
DAS28 -CRP at other timepoints and ACR20, 50 and 7 0 will be summarized 
descriptively.  
 
In addition, 90% and 95% CI for the risk ratio (RR) and  risk difference (RD) of ACR20, 
ACR50  and ACR 70 at week 24  between ABP 798 and rituximab (pooled US -licensed  
and EU -authorized rituximab,   US-licensed rituximab or EU-authorized rituximab ) will 
also be provided  and the outcome is descriptive .   
 
Product: ABP  798 
Clinical Study Protocol: 2013010 8 
Date:  20 March 2018  Page 7 of 7 
 
Confidential   
 
Other endpoints, RR and RD of ACR20 /50/70  at weeks 8, 12, 40, and 48, and  RR and 
RD of ACR50 and ACR70 at weeks 8, 12, 40, and 48 will be summarized descriptively 
by treatmen t. 
 
Section 3: Table of Contents Appendix 3 Title  
Replace:  
 
ACR Core Set Measurements  
 
With:  
DAS28 and ACR  Core Set Measurements  
 
 
 
3URGXFW$%3 
&OLQLFDO6WXG\3URWRFRO 
'DWH2FWREHU 3DJHRI 
&RQILGHQWLDO$5$1'20,=(''28%/(%/,1'678'<72&203$5(
3+$50$&2.,1(7,&6$1'3+$50$&2'<1$0,&6()),&$&<$1'
6$)(7<2)$%3:,7+5,78;,0$%,168%-(&76:,7+02'(5$7(
726(9(5(5+(80$72,'$57+5,7,6

6800$5<2)&+$1*(6

7HVW'UXJ  $%3
3URWRFRO1XPEHU   (XGUD&7QXPEHU 
6WXG\3KDVH   
'DWHDQG9HUVLRQ 2FWREHU9HUVLRQ

6SRQVRU
$PJHQ,QF
2QH$PJHQ&HQWHU'ULYH
7KRXVDQG2DNV&$86
&OLQLFDO5HVHDUFK2UJDQL]DWLRQ&52
35$+HDOWK6FLHQFHV
3DUN/DNH$YHQXH6XLWH
5DOHLJK1&86


&21),'(17,$/
3DJHRI
Product: A BP798
Clinical Study Protocol: 2013010 8
Date: 16October 2017 Page 2of 5
ConfidentialRationale:
This amendment is issued to make the following changes:
ï‚·To make minor, non -substantive grammatical and typographic corrections
(changes not detailed in this summary)
ï‚·To adjust the language regarding study treatment accountability logs to indicate a 
single log as opposed to logs for each subject
ï‚·To remove ACR20 from secondary efficacy endpoints
ï‚·To correct multiplicity adjustments and error rates for statistical analysis of 
pharmacokinetic variables
ï‚·To add the DAS28 core set measurements to Appendix 2
Page 79 of 82
Product: A BP798
Clinical Study Protocol: 2013010 8
Date: 01December 2016 Page 1of 21
ConfidentialA RANDOMIZED, DOUBLE -BLIND STUDY TO COMPA RE 
PHA RMA COKINETICS A NDPHA RMA CODYNA MICS, EF FICA CY A ND 
SAFETY OF A BP 798 WITH RITUXIMA B IN SUBJECT S WITH MODERA TE 
TO SEVERE RHEUMA TOID ARTHRITIS
SUMMA RY OF CHA NGES
Test Drug: ABP 798
Protocol Number: 20130108 EudraCT number: 2013 -005543 -90
Study  Phase: 1/3
Date and Version: 01December 2016 ; Version 2.0
Sponsor:
Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320 -1799 USClinical Research Organization (CRO):
PRA 
4130 ParkLake Avenue, Suite 400
Raleigh, NC 27612 US
CONFIDENTIA L
Product: A BP798
Clinical Study Protocol: 2013010 8
Date: 01December 2016 Page 2of 21
ConfidentialRationale:
This amendment is issued to make the following changes:
ï‚·To make minor, non -substantive grammatical and typographic corrections
(changes not detailed in this summary)
ï‚·To update Medical Monitor contact information
ï‚·To update International Council for Harmonisation ( ICH) terminology
ï‚·To update pharmacokinetics terminology for consistency with the Statistical 
Analysis Plan
ï‚·To clarify t he end of study period
ï‚·To clarify the end of trial date
ï‚·To modify the Inclusion Criteria as follows :
1.To specify subjects must have had intolerance or an inadequate response 
to one or more TNF inhibitor therapies
2.To specify that subjects must have completed at least 4 weeks of a TB 
prophylaxis regimen prior to enrollment
ï‚·To modify the Exclusion Criteria as follows :
1.To allow subjects with a positive hepatitis B surface antigen or hepatitis B 
core antibody result to enroll provided documentation of hepatitis B virus 
immunization is provided
2.To add adalimumab to the list of biologic therapies not allowed within 3 
months prior to first dose of investigational product
3.To add ocrelizumab to the list of prohibited prior treatments
ï‚·To change terminology from â€œlocal p racticeâ€ to â€œlocal guidanceâ€ to ensure 
investigators follow general treatment guidelines
ï‚·To add citations for the administration of investigational product intravenously
ï‚·To add visits to the list of rescue medication administration guidelines
ï‚·To specify the format of unique subject identifiers
ï‚·To specify randomization stratification in regards to prior biologic therapies used 
to treat rheumatoid arthritis
ï‚·To clarify the day pharmacokinetic sampling timeframe s
ï‚·To specify and clarify visit windows
ï‚·To specify that creatinine clearance will only be assessed at screening
ï‚·To clarify that C -reactive protein results will be blinded to study sites
ï‚·To correct terminology related to visual analog scales
Product: A BP798
Clinical Study Protocol: 2013010 8
Date: 01December 2016 Page 3of 21
Confidentialï‚·To specify the timeframe for performing screening asses sments and procedures
ï‚·To clarify treatment versus infusion terminology
ï‚·To add that differential was added to hematology tests
ï‚·To add additional pharmacokinetic parameters as outlined in the Statistical 
Analysis Plan